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Abstract
Luminescent quantum dot (QD) based probes have gained significance in the last decade
for optical imaging of cells, tissues and in bioassays as alternatives to conventional organic
fluorophores. The main objective of my PhD dissertation was to develop luminescent quantum
dot based bioassays for real time monitoring of enzyme activity and simultaneous detection of
several biomarkers. The quantum dot based bioassays developed will be potential tools in
identification and diagnosis of several ailments that interfere with normal living conditions of
human beings.
In Chapter 2 new liposome encapsulated quantum dot based fluorescence resonance
energy transfer (FRET) probes have been fabricated and characterized for monitoring the
enzymatic activity of phospholipase A2. The probes were able to detect the enzyme activity as
low as 0.0075 U/mL (PLA2 = 1500 U/mg) in 30 min. Further these FRET probes were also used
to screen the inhibition efficiencies of phospholipase A2 inhibitors.
Chapter 3 focuses on the first time synthesis and characterization of liposome
encapsulated InP/ZnS quantum dots while preserving the integrity of the liposomes. Results from
the experiments to assess photostability and effect of pH on the optical properties of InP/ZnS
QD-liposomes showed greater advantages over InP/ZnS quantum dots demonstrating their utility
as a potential tool in several biological applications such as bio imaging, bioassays and in
immunoassays.
Chapter 4 discusses the development of fluorescence based immunoassay for
simultaneous detection of the cardiac biomarkers troponin T and troponin I using CdSe/ZnS
quantum dots. The assay achieved a detection limit was 0.1 pg/mL for both biomarkers troponin

x

T and I. The method was highly specific for the both the biomarkers with no observed cross
reactivity. The multiplex assay was able to detect two biomarkers simultaneously that will yield
a high throughput diagnostic tool for heart attack.
A similar method discussed as above was used in chapter 5 for the simultaneous detection
of atherosclerosis biomarkers. The detection limits achieved in this study are comparable to the
detection limits of the biomarkers reported so far. Incorporation of QDs in silica beads before
conjugation to antibodies might improve detection limits that will also improve risk assessment.

Key words: Quantum dots, Liposomes, FRET, Phospholipase A2, QD-liposomes, Multiplexing,
Myocardial Infarction, Troponins, Atherosclerosis, biomarkers, biosensors, immunoassay.
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Chapter 1
Introduction
1.1 Objectives and Aims
The main objective of my PhD dissertation was to develop luminescent quantum dot
based bioassays for real time monitoring of enzyme activity and simultaneous detection of
several biomarkers. Luminescent quantum dots are potential alternatives to conventional organic
fluorophores as they offer several advantages particularly broad absorption range with narrow
symmetric emission spectrum. These advantages allows for simultaneous detection of multiple
color quantum dots upon illumination with single light source that in turn can be used to analyze
several analytes at the same time. My research work was specifically aimed at: i) fabrication and
characterization of liposome encapsulated quantum dots and using them as fluorescence
resonance energy transfer (FRET) based probes to monitor phospholipase A2 enzyme activity ii)
synthesis and characterization of cadmium free InP/ZnS quantum dots and encapsulating them
with liposomes iii) development of a fluorescence immunoassay for the simultaneous detection
of heart attack biomarkers troponin T and troponin I, and iv) further use the same method to
detect atherosclerosis biomarkers.
1.2 Significance
The majority of studies reported so far for monitoring the enzyme activity of
phospholipase A2 are focused on the use of fluorophores. However the fluorophores are
associated with several chemical and photo physical limitations like broad emission spectra, poor
photostability, and low quantum yields. As alternatives to conventional organic fluorophores
luminescent quantum dots have received great interest in the last decade for optical imaging of
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cells, tissues and in bioassays. The first project was to develop liposome encapsulated quantum
dot based FRET probes for monitoring phospholipase A2 enzyme activity and to screen the
inhibition efficiencies of phospholipase A2 inhibitors. This method demonstrates the possibility
to multiplex the assay in a 96 well plate and screen a large number of inhibitors simultaneously.
Recently, focus has been shifted to the synthesis of cadmium free quantum dots due to
cytotoxicity associated with cadmium though they are known to exhibit high quantum yields. InP
quantum dots are more popular because they are less cytotoxic and exhibit a wide emission range
from UV to NIR range of the electromagnetic spectrum which makes them ideal candidates for
in vivo applications as opposed to CdSe quantum dots. For the first time InP/ZnS quantum dots
were encapsulated with liposomes which not only enhance the optical properties of the quantum
dots but also make them biocompatible. The next two projects were aimed at multiplexing
quantum dots to develop fluorescence based immunoassays for simultaneous detection of
biomarkers that play crucial role in heart attack and atherosclerosis. The ability of detecting the
biomarkers simultaneously in a single assay reduces cost, saves time and improves the
assessment of risk.
1.3 Quantum Dots
Luminescent semiconductor nanocrystalline particles or quantum dots (QDs) are
composed of elements from groups II–VI (CdS, CdSe, CdTe, ZnO, ZnS, ZnSe), III–V (InP,
InAs, GaP, GaN, GaAs), and IV-VI (PbS, PbSe, PbTe) of the periodic table. The nanocrystals
usually have diameters ranging from 2-10 nm. The exciton Bohr radius defined as the average
distance between bound electron-hole pair is confined in quantum dots in all three dimensions.
Hence the nanoparticles have characteristics between bulk semiconductors and discrete
molecules. This phenomenon is called the quantum-confinement effect. Quantum confinement
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causes increased stress on the exciton that result in increased energy of the emitted photon. The
smaller the QDs, the less room for exciton separation, and more energy is required to form the
exciton and hence they emit at lower wavelengths (Scheme 1.1).

Scheme 1.1 Schematic representation of electronic structure of quantum dots due to quantum
confinement.
Because of the quantum confinement effect, QDs exhibit unique optical properties that
have several advantages over conventional fluorophores. The exceptional brightness of QDs
comes from a combination of efficient light absorption, large extinction coefficient and high
quantum yields up to 85%.1 QDs exhibit high photostability with regard to bleaching compared
to conventional fluorophores enabling highly sensitive detection and long observation times in
fluorescence microscopy.2 QDs also have narrow emission spectra and a large Stokes shift,
which is the difference between the wavelength of absorbed and emitted light.3 This large shift
allows easy separation of the fluorescence signal of QDs from excitation light source and multicolor imaging without crosstalk between different detection channels in fluorescence
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microscope. Additionally, QDs of different emission maxima can be excited by one single
wavelength, which eliminates the need for numerous excitation sources in the instrumental
setup.4 Quantum dots enable time-resolved detection as they have relatively long fluorescence
lifetime (20–50 ns) that significantly increases the signal-to-background ratio relative to cell auto
fluorescence (<5 ns).5
1.3.1 Synthesis of quantum dots
Similar to traditional chemical processes colloidal semiconductor nanocrystals are
synthesized from precursor compounds dissolved in solutions.6 The synthesis of
colloidal quantum dots is based on a three component system composed of precursors, organic
surfactants, and solvents. During synthesis size tuning of QDs is achieved by controlling the
relative concentrations, duration, temperature, and ligand molecules used. CdSe is a popularly
used semiconductor material because of its tunable absorption energies throughout the visible
region, availability of precursors for synthesis, and simple crystallization. The often used method
to synthesize CdSe quantum dots is pyrolysis of organometallic precursors CdO, Cd(Ac)2 and
CdCO3.7-9 The excited electron or hole can be trapped by surface defects, such as vacancies, local
lattice mismatches, and dangling bonds that lead to the nonradiative recombination, which will
result in the low quantum yield.10 A thin layer of high band gap semiconductor material like ZnS
is grown on the surface of quantum dots to decrease the effect of surface defects and to protect
surface atoms from oxidation and other chemical reactions.11-13 This process described as surface
passivation improves chemical stability and photostability, increases the emission quantum yield,
and reduces the toxicity by preventing leakage of Cd or Se to the surrounding environment.
CdSe/ZnS quantum dots have little future in the biomedical field due to their cytotoxicity,
though they have high fluorescence quantum yields.14, 15 InP quantum dots made from III-V
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semiconductor materials are very useful because of low toxicity and greater quantum size
effects.16-18 InP/ZnS core/shell quantum dots can be synthesized to emit into the near infrared
region that is ideal for in vivo applications. Even though InP/ZnS quantum dots are promising
for future applications, the studies of InP/ZnS QDs are less advanced due to their more difficult
synthetic chemistry and low quantum yields.19 Initially the quantum yields of InP nanocrystals
were improved from 20–40% by HF etching.14 In 2007 Peng et al reported InP/ZnS core–shell
quantum dot synthesis using fatty amine for which the quantum yields reached up to 40%.20 The
synthesis was similar to that for CdSe quantum dots and used relatively low reaction
temperatures below 200°C and used indium acetate and myristic acid as precursors. A one step
and one pot method for the synthesis of highly luminescent InP with QYs of up to 30% and
InP/ZnS QDs with QYs of up to 60% was reported by Nann et al.21 More recently, Reiss et al
synthesized InP/ZnS QDs in a single step with quantum yield up to 70%.22
1.3.2 Bioconjugation of quantum dots
The high quality quantum dots synthesized in organic solvents are insoluble in water, do
not have functional groups for bioconjugation and are thus non-biocompatible. In order to make
them biocompatible the hydrophobic coating ligands of luminescent quantum dots must be
replaced with bifunctional hydrophilic capping ligands or must be further coated with an
amphiphilic layer to impart water solubility and potential bioconjugation sites (Figure 1.1).
These treatments will facilitate their applications in biological systems. Various methods for the
improvement of quantum dot biocompatility and stability have been developed during the past
few years. One of the most commonly used methods is ligand exchange that involves the
replacement of hydrophobic ligands with bifunctional ligands in which one end binds to the
inorganic QD surface and the other end provides hydrophilicity. The hydrophobic capping
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ligands are often exchanged with thiol functionalized compounds such as mercaptoalkanoic
acids.23-27 The thiol binding to the ZnS surface is not very strong resulting quantum dots
aggregation over time.28 This instability is the limitation of capping quantum dots with thiol
containing ligands.

Figure 1.1 Representation of different approaches for conjugation of quantum dots to
biomolecules.
Another method is silica encapsulation, which involves the growth of a silica layer on the
surface of the quantum dots. Functional groups –SH and –NH2 on the surface of organosilane
molecules enable bioconjugation.29, 30 However, the method is very laborious, difficult to
reproduce, and the silica layer may be hydrolyzed.31 Yet another method is coating QDs with an
amphiphilic polymer and phospholipids. This approach is achieved by forming the layer on the
QD surface via hydrophobic interactions with the hydrophobic ligands.32 The polymer has a
hydrophilic exterior that makes the quantum dots soluble in aqueous solutions. However, this
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method limits many biological applications such as FRET measurements and endocytosis since
the size of the coated quantum dots becomes much larger.31 In addition to the above mentioned
methods there are several methods for developing water-soluble, biocompatible quantum dots.
Synthesizing high quality water soluble and stable quantum dots still remains an important area
of research in quantum dot based nanobiotechnology.
1.3.3 Biological application of quantum dots
Quantum dots are new generation of fluorescent probes that are promising tools in
biological applications as an alternative to commonly used organic fluorophores due to their
unique optical and chemical properties. Water soluble quantum dots have been extensively used
in protein assays,33-35 hybridization assays,36-38 and fluorescence resonance energy transfer
(FRET) based bioassays.39-41 They have also been used as labels for in vitro42-44 and in vivo45-47
imaging applications.
1.3.3.1 Quantum dots as FRET donors
Fluorescence resonance energy transfer (FRET) is a non radiative energy transfer from
the donor in excited state (D) to an acceptor (A) (Scheme 1.2). The energy transfer is a result of
long-range dipole-dipole interactions between the donor and acceptor.48, 49 Thus the fluorescence
intensity and lifetime of the donor is decreased and the acceptor fluorescence intensity is
increased. The rate of energy transfer depends on the following three important conditions: (i)
spectral overlap between the absorption spectrum of the acceptor and the fluorescence emission
spectrum of the donor; (ii) close proximity between the donor and acceptor molecules (typically
0.1-10 nm); and (iii) approximately parallel donor and acceptor transition dipole orientations.
FRET with optical microscopy, is a powerful photo-physical technique because of its high
sensitivity to changes in distance and relative dipole orientations between donor and acceptor.

7

FRET has been widely used to study protein-protein interactions, diffusion dynamics, protein
conformational changes, and detecting nucleic acids and peptides.50-52
Conventional fluorescent organic molecules have been extensively used as FRET pairs
due to their small size, compatibility with covalent coupling, and relatively large detectable
optical signal. However, organic fluorophores as FRET probes have narrow absorption spectra of
the acceptors, broad emission spectra of the donors, and low photo bleaching thresholds.
Quantum dots provide a potential solution to the above problems. QDs have been investigated as
FRET donors in place of traditional organic dyes because of their high photostability and unique
spectral properties.53-55

Scheme 1.2 Schematic illustration of fluorescence resonance energy transfer principle.
Several research groups reported FRET between quantum dots and organic dyes.56-58
Willard et al developed quantum dots as FRET donors in a protein-protein binding assay.59
Quantum dots were conjugated to bovine serum albumin as FRET donors and
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tetramethylrhodamine was bound to the protein as the FRET acceptors. In 2003, Medinta et al
first reported quantum dots based self-assembled nanoscale FRET biosensors for maltose
detection by coating CdSe/ZnS quantum dots with maltose binding protein molecules.60 Since
then, quantum dots based FRET biosensors have been reported to detect TNT,61 toxins,62 βlactamase,63 collagenase,64 DNA,65 RNA,66 and protein.67
1.3.3.2 Quantum dots in immunoassays
Immunolabeling is one of the widely explored bioapplications of quantum dots. QDs in
this category are more advanced than organic fluorophores due to their unique features like
photostability and multiplexing capability. The majority of the studies reported so far
demonstrated the use of QDs in target detection of various cancer markers within cells.68-70
These markers have been of pathological interest because they were either associated with
transformations or metastasis and were indicative of both the cancer and its progress. Other uses
include monitoring intracellular viruses, typing of blood cell antigens and visualization of drug
therapy effects in cellular metabolism.71, 72 Wilson et al used magnetic microspheres encoded
with three different quantum dots for the multiplexed detection of three different explosives.73
Gao et al described the use of tri-block copolymer coated quantum dots to perform in vivo
targeting and imaging of human prostate cancer cells.74 In 2007 Yezhelyev et al used a heterobifunctional cross linker to covalently attach multicolored QDs to antibodies that were used to
perform in situ molecular profiling of five different breast cancer biomarkers.75 Zhang et al in
2008, synthesized high quality multicolor amphiphilic copolymer coated
CdSe/CdS/Cd0.5Zn0.5S/ZnS QDs and used them for detecting human and rabbit antigens.76
Recently, Rauf et al developed QD bar coded magnetic microspheres based multiplexed
immunoassays via a layer-by-layer technique utilizing unique streptavidin/biotin interaction.77
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1.4 Liposomes
Liposomes are spherical artificial phospholipid vesicles that are used as models for
artificial cells, making them versatile tools in biology, biochemistry and medicine. Liposomes
form spontaneously when introduced into aqueous media. Similar to cell membranes, the
spherical phospholipids self-assemble to form a bilayer in which the phospholipid head groups
point toward the internal and external aqueous phases of the vesicles and the tails are enclosed in
a hydrophobic region. The liposomes are classified according to the compartmentalization of
aqueous regions between bilayers. In unilamellar liposomes, the aqueous compartment is
separated from the external solution by only one membranal bilayer. Unilamellar liposomes are
further classified based on the size. Small unilamellar liposomes (SUV) have 100 nm average
diameters while large unilamellar liposomes (LUV) have a maximal size of up to 10 m.
Multilamellar liposomes, consist of more than one bilayer each separated by an aqueous
compartment. The size, lamellarity (unilamellar or multilamellar) and lipid composition of the
bilayers influence many of the important properties like the fluidity, permeability, stability and
structure that can be controlled and customized to serve specific needs.

Scheme 1.3 Schematic representation of liposome structure.
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There are numerous approaches to prepare liposomes such as the injection method, the
dehydration/rehydration method, and the freeze thaw method. The synthesized liposomes are
characterized by light scattering, electronic or atomic force microscopy, and capillary
electrophoresis. Static and dynamic light scattering measurements are used to characterize the
size, size distribution, and shape of vesicles. The morphology of liposomes can be further
characterized by transmission electron microscopy (TEM) and atomic force microscopy
(AFM).78 The light scattering techniques provide average values of the physical characteristics of
liposome suspensions, while the TEM and AFM approaches provide information on individual
liposomes that may or may not represent the entire liposome population. Capillary
electrophoresis can also be used to obtain qualitative and quantitative information about the size
to charge ratio of liposomes as they are very stable under high electric fields.79, 80
Liposomes offer exceptional engineering ability due to their physicochemical
characteristics such as vesicle size, structure and surface versatility that can be modified with
established methods. They have been used to encapsulate and deliver oral vaccines as well as
anti cancer, anti inflammatory and hormonal drugs.81, 82 Liposomes can entrap large amounts of
fluorescent nanoparticles while providing high biocompatibility, and thus enhancing the
effectiveness of nanoparticles for detection in vivo and in vitro.83 Recently, fabrication of QDliposome vesicles gained importance as promising tools in nano-biotechnology. QDs have been
incorporated into phospholipid liposomes making them biocompatible while retaining
photoluminescence. The liposome quantum dot complexes have been applied as fluorescent
markers in immunoassays84 and also to deliver QDs into cytosol of oncogenic brain cells via
lipid mediated fusion with the cell membrane.85 QD-liposomes have also been used for tumor
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cell-targeting, imaging, and drug delivery functions in human epidermal growth factor receptor 2
over expressing tumor cells via receptor-mediated endocytosis.86
1.5 Phospholipases
Phospholipases are lipolytic enzymes that catalyze the hydrolysis of membrane
phospholipids. Their classification is based on cleavage of the bond in phospholipids (scheme
1.4). Phospholipase A1 and A2 selectively remove fatty acids from the SN1 and SN2 positions
respectively. Phospholipase B cleaves both SN1 and SN2 acyl bonds. Phospholipase C cleaves
the bond between glycerol and phosphate and phospholipase D hydrolyzes the amino alcohol
moiety from a phospholipid.

Scheme 1.4 Schematic illustration of phospholipase cleavage sites.
Phospholipase A2 (PLA2) are small proteins (ca. 14 kDa) containing multiple disulfide
bridges. The water-soluble forms of these extracellular enzymes are the most thoroughly studied
and have been used as model systems for the less tractable, membrane-bound forms, as well as
for the study of enzyme catalysis at lipid/water interfaces.87 PLA2 can be found in membrane-
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associated and soluble forms in almost all cell types, where they are believed to play an
important role in the normal biosynthesis and turnover of membrane phospholipids,88, 89 cellular
signaling,90 and protection of membranes from peroxidation damage.91 In addition, PLA2
enzymes have also been associated with the pathogenesis of numerous clinical inflammatory
processes.92, 93 PLA2 catalyzes the hydrolysis of the SN2 fatty acyl ester bond of phospholipids to
yield arachidonic acid and lysophospholipid.

Figure 1.2 Biosynthesis pathways of eicosanoids from arachidonic acid.
Arachidonic acid is converted by the cyclo-oxygenase (COX-1 or -2) pathway to produce
a variety of prostaglandins and thromboxanes (Figure 1.2). Specific prostaglandins can cause
constriction or dilation in vascular smooth muscle cells, cause aggregation or disaggregation of
platelets, control hormone regulation, control cell growth, decrease intraocular pressure, decrease
micro vascular permeability and cause platelet aggregation that can influence the course of
inflammatory episodes.94 Thromboxane is a vasoconstrictor, a potent hypertensive agent, and
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facilitates platelet aggregation. Leukotrienes play a powerful role in asthma, bronchoconstriction,
and other inflammatory responses. Also they play a role in cardiovascular and neuropsychiatric
illnesses. Lysophospholipids, another product of PLA2 enzymatic activity, produce platelet
activating factor, which causes a drop in blood pressure and reduced volume of blood pumped by
the heart. These effects can lead to shock and possibly death. Thus the inhibition of
phospholipase A2 which in turn blocks the formation of arachidonic acid is of great significance.
1.6 Myocardial Infarction.
Myocardial infarction (MI) or heart attack is the interruption of blood supply to some
parts of the heart muscles, causing cell death. This phenomenon occurs due the rupture of
a vulnerable atherosclerotic plaque, which is a collection of unstable lipids and white blood
cells especially macrophages in the wall of a coronary artery that leads to blockage. The
restriction in blood supply and shortage in oxygen can lead to damage or death (infarction) of
heart muscle tissue (myocardium) if left untreated for a long period of time. According to the
World Health Organization (WHO), heart attack is the leading cause of death for both men and
women worldwide. Every 34 seconds someone in the United States has a heart attack.95
The diagnosis of MI has been based on the “two out of three” criteria over several
decades as defined by WHO, including typical chest pain symptoms that last for more than 20
minutes, changes in serial electrocardiogram, and increase in the serum level of creatine kinaseMB and troponins.96 The WHO criteria have been refined in 2000 and recently in 2007 that gave
more importance to cardiac biomarkers especially troponins.97 According to this new criteria
cardiac troponin elevation accompanied by any of the typical symptoms are the diagnosis for
heart attack. Troponin is a complex of three regulatory muscle proteins troponin T (TnT),
troponin I (TnI), and troponin C (TnC) that play crucial role in muscle contraction. Troponin I
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binds to actin, troponin T binds to tropomyosin, and the third troponin C binds to calcium ions
(Scheme 1.5). When calcium ions bind to troponin C, the troponin changes shape, forcing
tropomyosin away from the actin filaments. This causes myosin cross-bridges to attach to actin,
and thus enable contractions.98 In the absence of calcium troponin C does not undergo
conformational change and therefore muscles remain intact.

Scheme 1.5 Schematic representation of Troponin complex.
Cardiac and skeletal muscles contain both troponin T and I, however the amino acid
sequences of the proteins are different.99 Troponin C is shared by cardiac and skeletal muscles
and therefore does not have cardiac specificity and is not used in assays for the diagnosis of
cardiac injury. Under normal conditions troponin T and I levels are very low but the
concentrations rise immediately following the heart attack. The release kinetics for both TnT and
TnI are similar and release within 4-13 hr following myocardial damage.100 Currently, several
immunoassay methods are available commercially for the detection of troponin I and troponin T
separately, most of them are based on ELISA and some of them based on fluoimmunoassay
technique.101-105 However, the current detection limits of troponin assays do not allow
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demonstration of normal cardiac troponin in healthy controls.106 Further lower detection limits
with improved assay sensitivity and precision would improve risk assessment.
1.7 Atherosclerosis
Atherosclerosis is a condition that results in accumulation of fatty materials such as
cholesterol causing the artery wall to increase in thickness. Atherosclerosis develops from lowdensity lipoproteins (LDL) that are oxidized by reactive oxygen species (ROS). LDL is in
globular shape that carries cholesterol from the liver to cells. A number of reactions occur to
repair the damage when oxidized LDL comes in contact with an artery wall, one such reaction is
the response of the body's immune system by sending specialized white blood cells
(macrophages and T-lymphocytes) to absorb the oxidized-LDL forming the specialized foam
cells. Accumulation of foam cells in the artery wall leads to formation of plaque, which can
constrict the blood vessels diameter. Although plaque can block blood flow, arteries respond to
this blockage by increasing their size. Consequently, plaque formation is not necessarily harmful.
However, some plaques become unstable and can rupture. Upon rupture, clot forming
compounds can be released, resulting in acute blockage of blood flow that can cause localized
tissue death. When such an event occurs in the heart, MI results. Blockages occurring in the
brain result in stroke. Plaque can also harden through calcification, resulting in reduction of the
blood flow and an increase in blood pressure.
Atherosclerosis is a chronic disease characterized by arterial lesions despite the lack of
any symptoms for many years.107 Atherosclerotic lesions or plaques are categorized as stable and
unstable.108 Stable atherosclerotic plaques are asymptomatic and are rich in extracellular matrix
and smooth muscle cells while unstable plaques are rich in macrophages, and foam cells and are
usually weak and prone to rupture. For a long time the diagnosis of cardiovascular disease in
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humans was based on severe narrowing, stenosis that was detected using angiography and stress
testing. Angiography is a conventional method of testing accumulated lipid-containing plaques in
the artery or atheroma, which shows motion or still images of inner space of the artery but does
not show atheroma within the arterial wall. All these methods are useful for diagnosis at later
stages of atheroma i.e. narrowing of arterial walls but do not help early detection. The current
most sensitive method, intravascular ultrasound detects and measures atheroma allowing
complete and accurate assessment than angiography within living individuals. Due to limitation
in cost and the method being body invasive, it is not used until after atheroma begins forming.
On the other hand CT scans have been the most effective method for detecting calcification
present in plaque however atheroma has to be advanced enough to have relatively large areas of
calcification within them.
Recent research efforts have repeatedly shown the use of biomarkers involved in different
stages of atherosclerosis like molecular proinflammatory biomarkers, plaque destabilization and
plaque rupture biomarkers to predict future cardiovascular occurrences not only in healthy
individuals, but also in patients with acute coronary syndrome.109 Therefore testing patients for
several of these markers will provide important information useful for predicting future
occurrence of atherosclerosis. Thus my fourth project aims at detecting the three biomarkers
monocyte chemoattractant protein-1 (MCP-1), interleukin 15 (IL-15), and interleukin 18 (IL-18)
that play a significant role in two important stages of atherosclerosis, fatty streaks and plaque
destabilization. MCP-1 is an important chemokine that is involved in regulated migration and
infiltration of monocytes/macrophages whose effects are mainly mediated through β-chemokine
receptors 2. In response to various cytokines, growth factors, and oxLDL110 monocytes express
MCP-1 and thus increase expression of MCP-1 in atherosclerotic lesions, particularly in
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macrophage-rich areas.111 In animal models, the extent of atherosclerosis and macrophage
infiltration into the atherosclerotic lesion is evaluated based on the expression of MCP-1.112
Interleukin 15 is another biomarker associated with atherosclerosis, it is a cytokine with
structural similarity to IL-2. IL-15 is found in high levels in plasma of patients with coronary
artery disease.113 The expression of IL-15 is found exclusively in fibrolipid and lipid-rich plaques
in complex foam cells.114 The up regulation of IL-15 in atherosclerotic lesions, stimulates T
lymphocytes.115 IL-18, is another biomarker and proinflammatory cytokine that is widely
expressed in various cell types. IL-18 enhances the expression of matrix metalloproteases
(MMPs)116-118 along with interferon eliciting helper T cell (Th1) immune response and these two
abilities of IL-18 characterize it as a crucial and potent mediator of atherosclerotic plaque
destabilization. In human atherosclerotic plaques, increased expression of IL-18 is seen in lesions
prone to rupture, and is localized mainly in plaque macrophages.119 In animal models, inhibition
of IL-18 by IL-18 binding protein reduced atherosclerotic plaque development and progression
supporting a proatherogenic role of IL-18.120
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Chapter 2

Quantum dot-liposome complexes as fluorescence resonance energy
transfer probes to monitor phospholipase A2 enzyme activity

2.1 Abstract
In the current chapter new liposome encapsulated quantum dot (QD) based fluorescence
resonance energy transfer (FRET) probes for monitoring the enzymatic activity of phospholipase
A2 have been fabricated and characterized. Luminescent CdSe/ZnS quantum dots in the lipid
bilayer acted as donor and the lipid bound membrane dye NBD acted as acceptor. As the
quantum dots were not attached covalently to the phospholipids they did not affect the enzyme
activity of phospholipase A2. The addition of phospholipase A2 to QD-liposomes demonstrated
changes in FRET signals due to cleavage of the SN2-acyl bond and release of NBD fluorophores
from the membrane. The changes in FRET signals were found to be dependent on phospholipase
A2 enzyme activity. The probes were able to detect enzyme activity as low as 0.0075 U/mL
(PLA2 = 1500 U/mg) in 30 min. The FRET format thus enables real time monitoring of the
enzyme activity. Further these FRET probes were also used to screen the inhibition efficiencies
of phospholipase A2 inhibitors. It is also possible to multiplex the assay in a 96 well plate and
screen large number of inhibitors simultaneously. Thus, the developed in vitro bioassay is
sensitive, reliable and can be easily performed to provide valuable information about
phospholipase A2 and its inhibitors for both medical and pharmacological fields.
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2.2 Introduction
Luminescent quantum dot (QD) based probes have been effectively utilized in the last
decade for optical imaging of cells and tissues and in bioassays as alternatives to conventional
organic flurophores.1,2 QDs have unique size-dependent chemical and physical properties
offering advantages like brightness, greater photostability, broad excitation wavelength range,
and size-tunable narrow, and symmetric emission spectra ranging from 400 to 2000 nm.3-8
However, quantum dot applications in bio-medical and clinical fields have been limited by the
disadvantage of QDs being capped with hydrophobic coating ligands.9,10 To overcome this
limitation, focus has been made on several synthetic strategies over the past several years to
make QDs water soluble and biocompatible. The attempts towards solubilization involved the
exchange of the hydrophobic surface ligands with hydrophilic thiol containing molecules like
mercaptoalkanoic acids.4,11-13 Some studies used other exchange ligands like dendrons,14
peptides,15,16 silica,17 block copolymers18, 19 or encapsulated QDs in water miscible phospholipid
micelles.20
Recently, fabrication of QD-liposome vesicles gained importance as a promising tool in
nano-biotechnology. QDs have been incorporated into phospholipid liposomes making them
biocompatible while retaining photoluminescence. Liposomes are concentric bilayered vesicles
consisting of a hydrophobic phospholipid bilayer surrounding a hydrophilic aqueous phase.
Liposomes offer exceptional engineering ability due to their physicochemical characteristics
such as vesicle size, structure and surface versatility that can easily be modified with established
methods. Liposomes can entrap large amount of fluorescent nanoparticles providing high
biocompatibility, thus they enhance the effectiveness of nanoparticles for detection in vivo and in
vitro.21 They have been used to encapsulate and deliver oral vaccines as well as anti cancer, anti
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inflammatory and hormonal drugs.22-24 Liposome quantum dot complexes have been applied as
fluorescent markers in immunoassays25 and also to deliver QDs into cytosol of oncogenic brain
cells via lipid mediated fusion with the cell membrane.26 Further, QD-liposomes were also used
for tumor cell-targeting, imaging, and drug delivery functions in human epidermal growth factor
receptor 2-overexpressing tumor cells via receptor-mediated endocytosis.27
Phospholipase A2 (EC 3.1.1.4) is a family of lipolytic extracellular enzymes that are
relatively small proteins (ca. 14 kDa) containing multiple disulfide bridges. Phospholipase A2
can be found in membrane-associated and soluble forms in almost all cell types, where they are
believed to play an important role in the normal biosynthesis28-31 and pathogenesis of various
inflammatory processes.32, 33 Phospholipase A2 catalyzes the hydrolysis of the SN2 fatty acyl
ester bond of phospholipids to yield arachidonic acid, and a lysophospholipid. Arachidonic acid
produces leukotrienes by the lipooxygenase pathway that play powerful role in asthama,
broncho-constriction, cardiovascular and neuropsychiatric illnesses. Lysophospholipids, another
product of phospholipase A2 enzymatic activity, produce platelet activating factor which causes a
drop in blood pressure and reduced pumping of blood by the heart, which leads to shock and
potentially death. Thus the measurement of phospholipase A2 enzyme activity can be of major
medical importance in drug discovery.
Phospholipase activity was monitored using traditional methods including titrimetry,
colorimetry, fluorometry and radiometry.34 Most of the methods are limited in terms of
sensitivity with the exception of fluorometry and radiometry. Radiometric methods are most
sensitive and most widely used but they are expensive, hazardous, laborious, and impractical
when dealing with large scale samples. Many of the initial fluorescence assays were
discontinuous and require phase separations to separate substrate and products. Wilton et al have
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described a continuous fluorescence displacement assay for PLA2 that involves monitoring the
loss of fluorescence when the fatty acid probe 11-(dansylamino)undecanoic acid is displaced
from liver fatty-acid-binding protein as a result of PLA2 activity.35 The assay detected enzyme
activity down to ~10 pmol/mL. Prestwich et al reported a fluorogenic assay for the detection of
PLA2 activity in real time using FRET with substrates having SN1-acyl chain labeled with
Dabcyl and SN2-acyl labeled with BODIPY fluorophore.36 Perez-Gilabert et al described a
spectrophotometric assay for the continuous and indirect measurement of PLA2 activity.37 The
activity of PLA2 is measured by the increase in absorbance at 234 nm due to the formation of
hydrogen peroxide from linoleic acid released from hydrolyses of dilinoleoyl
phosphatidylcholine. Recently, a fluorescence assay for PLA2 was reported by Whitten et al
where cationic poly(phenyleneethynylene) PPE derivatives physically adsorbed onto solid
nonporous borosilicate microspheres were subsequently coated with 1,2-dimyristoyl-sn-glycero3-[phospho-rac-(1-glycerol)] (DMPG).38 The lipid bilayer acts as a substrate for PLA2 and also
shields the fluorescence of PPE from quenching by 9,10-anthraquinone-2,6-disulfonic acid
(AQS). The amplified quenching of the polymer fluorescence by AQS is restored, as the DMPG
is digested by PLA2.
Many research labs including ours have recently developed quantum dot based
fluorescence resonance energy transfer based assays.39-44 Chang et al developed solution based
FRET assays using QDs as donors and gold nanoparticles as acceptors for proteolytic activity
measurements.44 Shi et al from our lab have covalently linked molecular fluorescent acceptors to
the surface of single quantum dot and used the FRET probes for real-time monitoring of protease
activity in solution.42 Most of the developed quantum dot based FRET assays were focused on
measuring the proteolytic activity. In the current study, a quantum dot based FRET assay was
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employed for lipase activity measurements. The quantum dot encapsulated liposome based
FRET probes were synthesized and characterized to monitor the enzymatic activity of
phospholipase A2. The phospholipid bilayer in QD encapsulated liposomes were also labeled
with acyl NBD fluorophores. The addition of phospholipase A2 to QD-liposomes showed
changes in FRET signals due to cleavage of SN2-acyl bond and release of NBD fluorophores
from the membrane (scheme 2.1). These changes in FRET signals were found to be
phospholipase A2 concentration dependent. Further the FRET probes were also used to screen the
inhibition efficiencies of phospholipase A2 inhibitors. This method demonstrates the possibility
to multiplex the assay in a 96 well plate and screen a large number of inhibitors simultaneously.
2.3 Experimental Methods
2.3.1 Materials and reagents. Technical grade (90%) trioctylphosphine oxide (TOPO),
technical grade (90%) trioctylphosphine (TOP), cadmium oxide (99.99%), selenium powder
(99.5%), lauric acid (98%), technical grade (90%) hexadecylamine (HDA), diethyl zinc (Zn(Et)2)
solution 1.0 M in heptane, hexamethyldisilathiane ((TMS)2S), methanol anhydrous (99.8%),
chloroform (99.5%), cholesterol, and phospholipase A2 from honey bee venom were purchased
from Sigma Aldrich. 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), and 1,2-dioleoyl-snglycero-3-phosphoglycerol (DOPG) were purchased from Avanti Polar Lipids. N-(fluorescein-5thiocarbamoyl)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine triethyl ammonium salt
(DHPE-fluorescein), 2-(6-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)hexanoyl-1-hexadecanoylsn-glycero-3-phosphocholine (NBD C6-HPC) were purchased from Invitrogen. All reagents were
used as received without further purification.
2.3.2 Synthesis of TOPO capped luminescent quantum dots. TOPO-capped CdSe/ZnS
quantum dots were prepared following a method first proposed by Peng6 with a slight
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modification.45 Briefly, 12-13 mg of cadmium oxide and 160-180 mg of lauric acid were mixed
under nitrogen atmosphere. The mixture was heated in a 100 mL three neck flask to slightly
above 200°C to fully dissolve the cadmium oxide (clear solution). Then, 2 g of TOPO and 2 g
HDA were added to the solution with constant stirring. Temperature was raised to 280°C before
being cooled down slowly. Upon reaching the desirable temperature 80 mg selenium powder
dissolved in 2 mL solution of TOP was rapidly injected into the solution under vigorous stirring.
For shell coating, a 2 mL TOP solution containing 250 μL (TMS)2S and 1 mL Zn(Et)2 was
injected drop-wise into the solution. The reaction mixture was kept at 180°C for one hour before
it was cooled to room temperature, washed three times with methanol, centrifuged at 4000 rpm
for 10 minutes each, and redispersed in chloroform. The concentration of this solution was found
to be 1 μM. The solution was stored at room temperature.
2.3.3 Encapsulation of quantum dots with liposomes. A 20 mM lipid stock solution was
prepared with 1:1:0.4 molar ratios of DOPC, DOPG, and cholesterol in chloroform. The
phospholipid stock solution was stored in a sealed vial at -10°C until use. A 100 μL aliquot of
the lipid stock solution was added to 75 μL of 1 μM TOPO coated quantum dots and dried under
nitrogen in a glass vial until all the chloroform was removed. A thin film formed at the bottom
of the glass tubes. 1 mL of 10 mM pH 7.4 PBS buffer was added to the above formed thin film
followed by sonication for 10 minutes and vortexing for 2 minutes. Unilamellar liposomes
containing quantum dots in the membrane were thus formed.
2.3.4 Fabrication of QD-NBD-liposome based FRET probes. A 100 μL aliquot of 20 mM
lipid stock solution was added to 75 μL of 1 μM TOPO coated quantum dots and then mixed
with varying volumes 0, 25, 50, 100, 200, and 500 μL of 100 μM NBD C6-HPC lipid molecules
dissolved in chloroform. These mixtures were further dried under nitrogen in a glass vial until all
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the chloroform was removed. A thin film formed at the bottom of the glass tubes. 1 mL of 10
mM pH 7.4 PBS buffer was added to the above formed thin film followed by sonication for 10
minutes and vortexing for 2 minutes. The corresponding NBD concentrations in the fabricated
QD-NBD-liposome based FRET probes are 0, 2.5, 5, 10, 20, and 50 μM respectively. Another
two fold dilution was performed on these samples to measure changes in FRET signals.
2.3.5 Enzyme activity and inhibition assays. A 100 μL aliquot of QD-NBD-liposome FRET
based probes with 20 μM NBD was dissolved in PBS buffer pH 8.0, following which varying
volumes of 0.5 mg/mL phospholipase A2 in PBS buffer containing 1 mM of CaCl2 were added to
make a final volume of 200 μL. Time-dependent spectral measurements were carried out
following the addition of phospholipase A2 using a fluorescence spectrometer or a digital
fluorescence spectral imaging system. Inhibition assays were monitored using fluorescence
spectroscopy. To carry out the inhibition assays, 50 μL of 100 μg/mL phospholipase A2 was
added to various concentrations of inhibitors to a total volume of 100 μL. Following 30-min
incubation, 100 μL of 75 nM QD-liposome FRET-based probes was added to the mixture and
FRET measurements were carried out to monitor to enzymatic reaction.
2.3.6 Fluorescence spectroscopy measurements. Excitation and emission spectra were
measured using a spectrofluorometer (Perkin Elmer), equipped with a 75-W continuous Xenon
arc lamp as a light source. The samples with DHPE-fluorescein were excited at 480 nm. For the
FRET assay all the samples were excited at minimum absorption wavelength of 375 nm to
reduce interference from direct excitation of NBD molecules. All other samples were excited at
400 nm. Emission scans were measured from 425-700 nm.
2.3.7 Digital fluorescence imaging microscopy. Luminescence images were obtained using a
digital inverted fluorescence microscope (Olympus IX71) equipped with a 100 W mercury lamp
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as a light source. The fluorescence images were collected via a 20 X microscope objective with
numerical aperture = 0.5. A filter cube containing a 380±20 nm band-pass excitation filter, a 425
nm dichroic mirror, and a 450 nm long pass emission filter was used to ensure spectral imaging
purity. Digital point controller (DP72) was used for digital imaging. An exposure time of 100
ms was typically used to acquire the fluorescence images of QD based probes.
2.3.8 Cryo-transmission electron microscopy measurements. Sample preparation for cryotransmission electron microscopy was carried out in a temperature and humidity controlled
chamber. A specimen grid was dipped into a suspension and withdrawn, and excess liquid was
blotted away. Thin films were formed between the bars of the grids. To vitrify these thin films,
the grid was shot into melting ethane. The grids with vitrified thin films were analyzed with a
JEM2010 high resolution transmission electron microscope (JEOL, Tokyo) at -170°C using a
Gatan-626 cryo-specimen holder and cryotransfer system (Gatan, Warrendale, PA). The
micrographs were collected at 120 kV. This microscope is equipped with a Gatan 2048- 2048
CCD camera and a Gatan energy filter.
2.4 Results and Discussion
2.4.1 Characterization of QD-liposomes. Luminescent CdSe/ZnS quantum dots were
successfully encapsulated into DOPC, DOPG, Chol (1:1:0.4) liposomal bilayer membranes
rendering the quantum dots water soluble. During the encapsulation process the hydrophobic
coating on the surface of QDs interacts with hydrophobic regions of liposomes via hydrophobic
interactions while the hydrophilic region of liposome is exposed to the water phase.
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Figure 2.1 (a) Emission spectra, and (b) normalized emission spectra of TOPO coated quantum
dots in chloroform (red line) and liposome encapsulated quantum dots in PBS pH 7.2 buffer
(green line) at 50 nM concentration of quantum dots. Digital fluorescence microscopic images of
(c) liposome encapsulated quantum dots with exposure time of 100 ms, and (d) liposome
encapsulated fluorescein with exposure time of 100 ms.
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The liposome encapsulated quantum dots were characterized for optical properties using
a spectrofluorometer and digital fluorescence imaging microscopy. Figure 2.1 (a, b) are the
emission and normalized spectra of TOPO coated quantum dots and liposome encapsulated
quantum dots respectively, at the same concentration of quantum dots. The normalized spectra
show that the optical properties of CdSe/ZnS quantum dots were well preserved even after
encapsulation with liposomes. Figure 2.1 (c, d) are the fluorescence microscopic images of QDliposomes and fluorescein (lipid membrane dye)-liposomes. It is evident from these images that
the QD-liposomes are brighter than fluorescein-liposomes and also had low background noise
compared to fluorescein-liposomes. Also the photo bleaching of the fluorescein containing
liposomes can be seen (Figure 2.1d) while the QD-liposomes were pretty stable under light.
Cryo-transmission electron microscopy was employed to study the structural
characteristics of the liposome encapsulated quantum dots. The results as depicted in figure 2.2a
show that the quantum dots are concentrated in the liposome bilayer membrane that are seen as a
dense bilayer. The microscopic image 2.2b is a control without quantum dots inside the
liposomal membrane that do not show dense bilayers as QD-liposomes. Also at lower
concentrations of quantum dots, the structures of the QD-liposomes were almost spherical in
shape where as at the higher concentration of QDs, some degree of deformation of the vesicle
structures was observed, visualized as elongated and deformed vesicular structures in the images
(figure 2.2d). The cryo-TEM results were in agreement with the previous work by Al Jamal et
al.29
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Figure 2.2 Cryo-transmission electron microscopy images of quantum dot containing liposomes
at 50 nM (a, c), at 500 nM QD concentration (d), and liposomes without quantum dots (b).
2.4.2. Fabrication of FRET probes. After characterization of QD-liposomes, the complexes
were used as fluorescence resonance transfer energy based probes to monitor enzyme activity of
phospholipase A2. The composition of the QD-liposomes in 1:1:0.4 molar ratio of
DOPC:DOPG:chol provides the negative charge and the unsaturation on the liposome membrane
that is necessary for phospholipase A2 enzyme activity.
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Figure 2.3 Emission spectra of QD-NBD-liposome based FRET probes at (a) 0, (b) 1.25, (c) 2.5,
(d) 5, (e) 10, and (f) 25 μM of NBD C6-HPC lipid molecule concentration. λex: 375nm.
Quantum dots present in the lipid bilayer will act as donor and the lipid membrane dye
NBD will act as acceptor. Different concentrations of NBD C6-HPC lipid molecules of final
concentrations ranging from 0 to 25 μM were incorporated into QD-liposomes and the probes
were characterized using spectrofluorometer and digital fluorescence microscope. When excited
at 375 nm, the absorbance minimum of NBD, to avoid direct excitation of NBD, it was observed
that the fluorescence resonance energy was transferred from the quantum dot emitting at 480 nm
to the NBD molecule emitting at 540 nm. This result is represented in figure 2.3 as increased
NBD intensities and decreased QD intensities at increasing concentrations of NBD.
2.4.3. Enzyme activity of phospholipase A2. FRET based probes were used to monitor the
enzymatic activity of the phospholipase A2. Phospholipase A2 is an enzyme that hydrolyzes
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phospholipids into fatty acids and other lipophilic substances. NBD is labeled on the acyl chain
of phospholipids as shown in scheme 2.1. The enzyme phospholipase A2 specifically recognizes
the SN2 acyl bond of phospholipids and breaks away NBD from the lipid membrane. As a result
energy transfer can no longer takes place as demonstrated by a decreased FRET signal.

Scheme 2.1 Schematic representation of QD-liposome based FRET probes for monitoring
phospholipase A2 enzyme activity.
Figure 2.4 shows the emission spectra of QD-liposome based FRET probes at increasing
phospholipase A2 enzyme activities from 0-75 U/mL. The spectra were recorded 30 min after the
addition of phospholipase A2 to the QD-liposome solution. An increase in the quantum dot
emission intensities at 480 nm and a decrease in the NBD emission intensities at 540 nm were
clearly observed, suggesting a significant decrease in the FRET efficiency with increase in
phospholipase A2.

38

Figure 2.4 Emission spectra of QD-NBD-liposome based FRET probes with 10 μM NBD and at
increasing phospholipase A2 enzyme activities: (a) 0, (b) 1.5, (c) 7.5, (d) 15, (e) 37.5, and (f) 75
U/mL. λex: 375nm.
A non-linear dependence of normalized Fd/Fa on phospholipase A2 was observed where,
Fd and Fa are the emission intensities of the quantum dot FRET-based probes at 480 nm
(quantum dot donors) and 540 nm (NBD acceptors) respectively, when excited at 375 nm. Fd/Fa
values were normalized to (Fd/Fa)0; the ratio of Fd/Fa prior to adding phospholipase A2 to the QDliposome solutions. The dependence of FRET signal on phospholipase A2 concentration was
attributed to the enzymatic cleavage of the phospholipid molecules that release NBD molecules
from the lipid molecule into the solution. The NBD molecule is hydrophilic in nature and
preferentially releases into aqueous phase after cleavage decreasing the FRET efficiency.
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Control experiments were performed with QD-liposomes without NBD labeling and
NBD-liposomes without quantum dots. Adding phospholipase A2 did not result in a significant
change of the emission intensities. These measurements ruled out the possibility of nonspecific
adsorption of phospholipase A2 on quantum dots surface that might alter resulting emission
intensities. Also the possibility that the decrease in the fluorescence intensity of NBD during
FRET enzymatic assays resulted from a change in the chemical environment of the NBD
molecules during the enzymatic cleavage by phospholipase A2 was precluded.
Figure 2.5 shows the temporal dependence of the ratio Fd/Fa at increasing phospholipase
A2 enzyme activities ranging from 0 to 75 U/mL (ex: 375 nm). Fd/Fa increases with increase in
incubation time and with the increase in phospholipase A2 enzyme activity. It was possible to
detect the enzymatic activity as low as 0.0075 U/mL (PLA2 = 1500 U/mg) in 30 min at room
temperature. Control experiments using QD-liposome based probes in the absence of
phospholipase A2 showed almost no changes in the FRET signal which clearly indicate that the
changes in FRET signals associated with QD-liposome probes are due to the enzymatic activity
of phospholipase A2.
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Figure 2.5 Time dependence of QD-NBD-liposome probes with 10 μM NBD and at increasing
phospholipase A2 enzyme activities: (a) 0, (b) 0.075, (c) 1.5, (d) 15, and (e) 75 U/mL. λex:
375nm. The ratio Fd/Fa was normalized to (Fd/Fa)0; the ratio of Fd/Fa prior to adding
phospholipase A2 to the QD-liposome solutions.
Images 2.6a and 2.6b are the digital fluorescence microscopic images of QD-liposomes
and QD-liposomes labeled with NBD respectively. QD-liposomes show their characteristic blue
emission while the QD-liposomes labeled with NBD emit bluish green light due to FRET
between the quantum dots and NBD molecules. Image 2.6c shows the fluorescence image of the
quantum dot FRET-based probes 30 min following the addition of 75 U/mL phospholipase A2. It
was seen that the emission color of the quantum dots turned blue due to enzymatic cleavage of
the phospholipid molecule that released NBD molecules to the solution and restored the blue
emission color of the quantum dots.
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Figure 2.6 Digital fluorescence microscopic images of (a) only QD-liposomes showing blue
emission (b) QD-NBD-liposomes with 10 μM NBD showing green emission due to FRET
between quantum dots and NBD (c) QD-NBD-liposome based probes with 10 μM NBD after
incubating for 30 min with 75 U/mL phospholipase A2 enzyme activity. Emission spectra are
provided as insets.
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a)

b)

Figure 2.7 a) Time dependence of Fd/Fa at 75 U/mL of phospholipase A2 activity and increasing
concentrations of its inhibitor MJ33. (a) control in the absence of phospholipase and inhibitor,
(b) 50 μg/mL, (c) 1 μg/mL, (d) 0.1 μg/mL, and (e) 0 μg/mL. b) time dependence of Fd/Fa at 75
U/mL of phospholipase A2 activity and increasing concentrations of its inhibitor OBAA. (a)
control in the absence of phospholipase and inhibitor, (b) 125 μg/mL, (c) 50 μg/mL, (d) 25
μg/mL, and (e) 0 μg/mL.
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2.4.4. Screening enzyme inhibitors. The QD-liposome probes were used to screen the inhibition
efficiencies of two phospholipase A2 inhibitors: 1-hexadecyl-3-(trifluoroethyl)-sn-glycero-2phosphomethanol (MJ33) and 3(4octadecyl) benzoylacrylic acid (OBAA). Figure 2.7a shows the
temporal dependence of the ratio, Fd/Fa of quantum dot based probes with increasing
concentrations of inhibitor MJ33 from 0 to 50 μg/mL at 75 U/mL of phospholipase A2 activity.
Figure 2.7b shows the temporal dependence of the ratio Fd/Fa with increasing concentrations of
OBAA from 0 to 125 μg/mL at 75 U/mL of phospholipase A2 activity. The rate of increase of
Fd/Fa was found to be dependent on the concentration of the enzyme inhibitors. The trend
towards decreasing phospholipase A2 enzyme activity with increase in concentrations of enzyme
inhibitors was observed for both MJ33 as well as OBAA. However, it was seen that the
inhibition efficiency of MJ33 was higher than the inhibition efficiency of OBAA at 50 μg/mL.
2.4.5. Advantages offered by QD based FRET probes. The unique feature of this work is the
platform of liposome encapsulated QDs that can be prepared using commercially available
substrates. Since the quantum dots are not attached covalently to the phospholipids they do not
affect the enzyme activity of phospholipase A2. The FRET format enables real time monitoring
of the enzyme activity. The QD based FRET probes were able to detect the enzyme activity as
low as 0.0075 U/mL (PLA2 = 1500 U/mg) in 30 min at room temperature which is the best
detection limit attained so far in comparison to 0.05 U/mL of commercially available detection
kit. These FRET probes were further used to screen the inhibition efficiencies of PLA2 inhibitors.
QD based FRET probes allow for multiplexing and screening large number of inhibitors
simultaneously. The method is also suitable for both kinetic analysis and large-scale screening
using automated readers for 96-well plates.
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2.5 Conclusions
Liposome encapsulated CdSe/ZnS quantum dots have been synthesized successfully
making the quantum dots water soluble and biocompatible. The optical characterization revealed
that the properties of quantum dots were well preserved even after encapsulation with liposomes.
Structural characterization using cryo-TEM was in accordance with previous work showing
dense bilayers for QDs encapsulated liposomes. Further to fabricate QD liposome based FRET
probes, NBD bound to acyl chain of phospholipids was incorporated into QD liposomes. These
complexes were then used as FRET based probes to monitor the enzyme activity of
phospholipase A2. The FRET signal changes were found to be phospholipase A2 enzyme activity
dependent. Since the quantum dots were not attached covalently to the phospholipids, they did
not affect the enzyme activity of phospholipase A2. The probes were able to detect the enzymatic
activity as low as 0.0075 U/mL (PLA2 = 1500 U/mg) in 30 min. Therefore, the FRET format
enables real time monitoring of the enzyme activity. Further these FRET probes were also used
to screen the inhibition efficiencies of two phospholipase A2 inhibitors 1-hexadecyl-3(trifluoroethyl)-sn-glycero-2-phosphomethanol and 3(4octadecyl)benzoylacrylic acid. It is also
possible to multiplex the assay in a 96 well plate and screen a large number of inhibitors
simultaneously. Thus the developed in vitro bioassay is sensitive, reliable and can be easily
performed to provide valuable information about phospholipase A2 and its inhibitors to both the
medical and pharmacological fields.
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Chapter 3

Synthesis and characterization of liposome encapsulating InP/ZnS
quantum dots

3.1 Abstract
InP quantum dots (QDs) are popular III-V semiconductor nanocrystals, however, studies
of InP quantum dots are less advanced in comparison to II-VI semiconductor nanocrystals
because of their difficult synthetic chemistry and low quantum yield. This work for the first time
focuses on the synthesis and characterization of liposome encapsulated InP/ZnS quantum dots.
InP/ZnS-liposome complexes were successfully synthesized preserving the integrity of the
liposomes. A comparative photostability study of InP/ZnS QD-liposomes with 16mercaptohexadecanoic acid (MHDA) coated QDs and InP/ZnS QDs showed enhanced stability
of InP/ZnS QDs after encapsulation. After 60 min of continuous irradiation, the fluorescence
intensity of InP/ZnS QDs decreased to 57% of the original intensity, whereas MHDA coated
QDs and InP/ZnS QD-liposomes decreased by only 30% and 27% respectively. Further the
effect of pH on the emission of InP/ZnS-liposome complexes was also studied, showing only
10% variation in the PL intensity of InP/ZnS QDs. Thus InP/ZnS-liposomes exhibit greater
advantages over InP/ZnS quantum dots demonstrating their utility as a potential tool in several
biological applications such as bioimaging, bioassays and immunoassays.
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3.2 Introduction
Quantum dot based probes have received great interest in the last two decades for optical
imaging of cells, tissues and in bioassays as an alternative to conventional organic flurophores.1,2
The majority of the research has focused on the use of II/VI luminescent quantum dots such as
CdSe or CdSe/ZnS as probes in several biological applications.3-8 Also there are studies that
reported the use of CdTe quantum dots for near infrared bioimaging.9 Despite several advantages
offered by II/VI type QDs, complete replacement of organic fluorophores is limited due to
cytotoxicity associated with the individual ions present in the quantum dots.10-12 The limitation is
overcome by the growth of thick ZnS shell on top of the CdSe or CdTe nanoparticles making
them less toxic. The ZnS shell inactivates the non-radiative recombination sites on the core
surface of the quantum dots to improve the quantum yield; it also acts as a barrier preventing the
contact of CdSe with the surrounding solvent avoiding dissolution. However, the ZnS shell does
not provide permanent and complete protection; therefore, the quantum dots are not completely
safe for biological applications.
The main advantage of III-V semiconductor nanocrystals over II-VI quantum dots is the
robustness of the covalent bond as opposed to the ionic bond. The more covalent bond is much
less likely to allow ionization and subsequent dissolution of the ions, making the particles less
cytotoxic. Among III-V semiconductor materials InP is popular, due to its bulk band gap of 1.35
eV that enables quantum dots to have photoluminescence emission wavelengths ranging from
blue to the near infrared. Thus InP quantum dots serve as alternatives to the frequently used
CdSe quantum dots for several applications including bio-labeling, light emitting devices,
photovoltaic cells, quantum dot lasers.1,13-15 However, quantum yield (QY) of III-V quantum dots
is less than 1% due to surface traps and dangling bonds in the crystal lattice and high activation
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barrier for de-trapping as compared to II-VI semiconductors.16-18 Initially the quantum yields of
InP NCs were improved to 20–40% by HF etching.19 Recently Peng et al reported InP/ZnS core–
shell quantum dots synthesis using fatty amine for which the quantum yields reached up to
40%.20 A one step and one pot method for the synthesis of highly luminescent InP with QYs of
up to 30% and InP/ZnS QDs with QYs of up to 60% was reported by Nann et al.21 More
recently, Reiss et al synthesized InP/ZnS QDs in a single step with quantum yield up to 70%.22
Liposomes are concentric bilayered vesicles consisting of a hydrophobic phospholipid
bilayer surrounding a hydrophilic aqueous phase. Liposomes offer exceptional engineering
ability because of their physicochemical characteristics such as lipid vesicle size, lipid vesicle
structure and surface versatility that can be easily modified with established methods. Liposomes
can entrap large amounts of fluorescent nanoparticles while providing high biocompatibility and
thus enhancing the effectiveness of nanoparticles for detection in vivo and in vitro.23 Therefore
they have been used to encapsulate and deliver oral vaccines as well as anticancer,
antiinflammatory and hormonal drugs.24-26 Recently, research involving the fabrication of
liposome-quantum dot vesicles gained more importance as a promising tool in nanobiotechnology. Liposomes and nanoparticles together are used as novel tools extensively in
pharmacological profile to retain biocompatibility and physio-chemical characteristics of lipid
bilayer and luminescent characteristics of QDs for therapeutic and diagnostic applications.
Cationic liposomes were used to deliver non-targeted CdSe/ZnS quantum dots into the cytosol of
oncogenic brain cells via lipid mediated fusion with the cell membrane.27 In another study,
researchers were able to internalize cationic lipid QDs in human epithelial lung tumor cells in
vitro and human cervical carcinoma xenografts in vivo and showed that they were able to
monitor intracellular trafficking inside the cells.28 Recently, it was seen that QD-immuno
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liposomes were capable of tumor cell-targeting, imaging, and drug delivery functions by
synthesizing QD-immuno liposomes that selectively and efficiently internalized in human
epidermal growth factor receptor 2 over expressing tumor cells via receptor-mediated
endocytosis.29 Furthermore, Yang et al demonstrated the targeting and imaging ability of folate
receptor targeted liposomes containing CdTe QDs in the human uterine cervix cancer cell line.30
In the current study, for the first time, liposome encapsulating InP/ZnS quantum dots
were successfully synthesized. The structure and optical properties were characterized using
cryogenic transmission electron microscopy, dynamics scattering light measurements and
spectroflourometry. A comparative photostability study of InP/ZnS QD-liposomes with 16mercaptohexadecanoic acid (MHDA) coated QDs and InP/ZnS QDs was performed. Further the
effects of pH and quantum dot concentration on the emission intensity of QD-liposomes were
also studied. The results suggest greater advantages of InP/ZnS-liposome complexes than the
InP/ZnS quantum dots and thus allowing wide range of biological applications such as
bioimaging, bioassays and immunoassays.
3.3 Experimental Methods
3.3.1 Materials and reagents. Indium acetate (99.99%), myristic acid (99%), 1-dodecanethiol
(98%), 1-octylamine (99%), 1-octadecene (90%), sulfur (99.9%), zinc stearate (90%), methanol
anhydrous (99.8%), chloroform (99.5%), 16-mercaptohexadecanoic acid, dihexadecyl phosphate,
cholesterol were purchased from Sigma Aldrich. Tris(trimethylsilyl)phosphine (P(TMS)3, 95%)
was purchased from Alfa Aesar. Dimyristoylphospatidylcholine (DMPC) was purchased from
Avanti Polar Lipids. N-(fluorescein-5-thiocarbamoyl)-1,2-dihexadecanoyl-sn-glycero-3phospho-ethanolamine triethyl ammonium salt (DHPE-fluorescein) was purchased from
Invitrogen. All reagents were used as received without further purification.
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3.3.2 Synthesis of luminescent InP/ZnS quantum dots. InP/ZnS quantum dots were
synthesized by following the procedure of Peng et al.20 Briefly, 0.4 mmol of indium acetate, 1.2
mmol of myristic acid, and 5ml of octadecene were loaded into a three-neck flask. The mixture
was heated to 180ºC under argon flow, for 30 min. Then a solution containing 0.2 mmol of
P(TMS)3 and 2.4 mmol 1-octylamine made in glove box was injected rapidly into the hot
reaction mixture and allowed 60 min to react. For the growth of ZnS shell, the reaction solution
was cooled down to 150ºC. Zinc stearate and sulfur precursors were added consecutively to the
reaction flask with the InP nanocrystals, waiting for 10 min between each injection at 150ºC.
After that, the temperature was increased to 230ºC for 20 min to allow the growth of the ZnS
shell. The reaction was cooled down to room temperature and the nanocrystals were precipitated
with methanol and centrifuged at 4000 rpm for 20 minutes three times. The precipitate was then
redispersed in chloroform.
3.3.3 Encapsulation of InP/ZnS quantum dots into liposomes. A 20 mM lipid stock solution
was prepared with a 5:4:1 molar ratio of dimyristoylphospatidylcholine, cholesterol, and
dihexadecyl phosphate in chloroform. This phospholipid composition provides maximum
structural stability of liposomes stored at room temperature.31 The phospholipid solution was
stored in a sealed vial at -10°C until use. A 100 μL aliquot of the stock solution was added to 100
μL of 2 μM InP/ZnS quantum dots and dried under nitrogen in a glass vial until all the
chloroform was removed. A thin film was formed at the bottom of the glass tubes. 1 mL of 10
mM pH 7.4 PBS buffer was added to the above formed thin film. The sample was sonicated for
5-10 minutes and vortexed for 2 minutes resulting in the formation of unilamellar liposomes.
3.3.4 Fluorescence spectroscopy measurements. Excitation and emission spectra were
measured using a spectrofluorometer (Molecular Probes, SpetraMax M2), equipped with a with a
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75-W continuous Xenon arc lamp as a light source. The samples with DHPE-fluorescein were
excited at 480nm. Samples having QDs were excited at 400nm. Emission scans were measured
from 450-700nm.
3.3.5 Digital fluorescence imaging microscopy. Luminescence images were obtained using a
digital luminescence imaging microscopy system. The system consisted of an inverted
fluorescence microscope (Olympus IX71) equipped with a 100 W mercury lamp as a light
source. The fluorescence images were collected via a 20 X microscope objective with numerical
aperture = 0.5. A filter cube containing a 420 ±10 nm band-pass excitation filter, a 450 nm
dichroic mirror, and a 480-nm long pass emission filter was used to ensure spectral imaging
purity.

Scheme 3.1 Schematic illustration of light path through filter cube in an inverted fluorescence
microscope.
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Schematic representation of typical light path through filter cube of an inverted
fluorescence microscope was shown in scheme 3.1. The filter cube consists of three types of
filters: excitation filter, emission filter and dichromatic beam splitter (dichroic mirror).
Excitation filter permits only selected wavelengths from the illuminator to pass through on the
way toward the specimen. Emission filter is designed to suppress or absorb the excitation
wavelengths and permit only selected emission wavelengths to pass toward the eye or other
detector. A dichroic mirror is a specialized filter which is designed to efficiently reflect
excitation wavelengths and pass emission wavelengths. It is positioned in the light path after the
excitation filter but before the emission filter. Dichroic mirror is oriented at a 45 degree angle to
the light passing through the excitation filter and at a 45 degree angle to the emission filter as
illustrated in Scheme 3.1.
3.3.6 Transmission electron microscopy. Transmission electron microscope images were taken
on JEOL 2000EX microscope at an accelerating voltage of 200 kV. One drop of InP/ZnS
quantum dots (emitting at 520 nm) in chloroform solution was deposited on a copper grid
covered by an amorphous carbon film and allowed to dry overnight.
3.3.7 Dynamic light scattering measurements. The average particle size and size distribution
were determined by dynamic light scattering with a Malvern Zetasizer Nano ZS (Malvern
Instruments Ltd., U.K.) at 25°C. About 0.2 mL of each liposome suspension was diluted with 2.5
mL of water immediately after preparation. Each experiment was repeated three times. The zeta
potential was also measured by using a the Zetasizer ZS instrument. Zeta limits ranged from-150
to 150 V. Strobing parameters were set as follows: strobe delay -1.00, on time 200.00 ms, and off
time 1.00 ms.
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3.4 Results and Discussion
InP/ZnS quantum dots were synthesized as described by Peng et al.20 Different sizes of
InP/ZnS quantum dots with emission maxima ranging from 450 nm to 680 nm were prepared by
varying the molar ratios of In and P precursors (Figure 3.1). The synthesized InP/ZnS quantum
dots were characterized using spectrofluorometer and transmission electron microscopy.

Figure 3.1 Normalized emission spectra of different InP/ZnS quantum dots in chloroform
emitting from 450nm to 680nm.

Figure 3.2 Transmission electron microscopic images of InP/ZnS QDs emitting at 556 nm.
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(a)

(b)

Figure 3.3 (a) EDS spectrum of InP/ZnS QDs showing the individual peaks of In, P, Zn, and S
elements. (b) elemental analysis showing a molar ratio of 1:0.4 for In: P in InP/ZnS QDs.
Figure 3.2 shows the transmission electron microscopic images at different
magnifications of InP/ZnS quantum dots emitting at 556 nm. The corresponding EDS spectrum,
shown in Figure 3.3 indicates the presence of individual peaks of In, P, Zn, and S elements
confirming the composition of InP/ZnS quantum dots. Also, elemental analysis confirmed a
molar ratio of 1:0.4 for In: P in InP/ZnS quantum dots comparable to the starting material ratio of
In: P 1:0.5.
InP/ZnS quantum dot encapsulated in liposomes have been successfully prepared DMPC,
Chol, DP (5:4:1) liposomal bilayer membrane rendering water solubility to the quantum dots.
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This phospholipid composition provides maximum structural stability to liposomes stored at
room temperature. During the encapsulation process, the surface of QDs interacts with
hydrophobic regions of the liposomes via hydrophobic interactions and the hydrophilic region of
the liposome is exposed to the water phase. The liposome encapsulated quantum dots were
further characterized for optical properties using spectroflourometry and digital fluorescence
imaging microscopy.

Figure 3.4 (a) Emission spectra and (b) normalized emission spectra of InP/ZnS quantum dots in
chloroform (red) and liposome encapsulated InP/ZnS quantum dots (green) in pH 7.2 PBS buffer
at the same concentration of quantum dots.
Figure 3.4 (a, b) are the emission and normalized emission spectra of InP/ZnS quantum
dots in chloroform and liposome encapsulated InP/ZnS quantum dots in pH 7.2 PBS buffer with
the same concentration of quantum dots. As quantum dots are surrounded by two different
solvent environments in TOPO coated QDs and in liposome encapsulated QDs there might be
some difference in the emission intensities as observed in Figure 3.4a. The normalized spectra
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show that the optical properties of InP/ZnS quantum dots were well preserved even after
encapsulation with liposomes.
The structural characteristics of these InP/ZnS QD-liposomes were studied by dynamic
light scattering. The mean diameter of these QD-liposomes was found to be 102.7+6.8 nm,
similar with the liposomes consisting of the equivalent lipids alone (100.9+3.0 nm). In particle
size analysis system, the polydispersity index is used to describe the spread in particle diameters
produced in a sample of particles. As the index approaches zero, the size range produced
becomes narrower. The polydispersity index of the liposomes and QD-liposomes were 0.17+0.04
and 0.290+0.01 respectively indicating narrow size distribution. The surface charge
characteristics measured using zeta potential was found to be -30 mV for liposomes and -29 mV
for QD-liposome vesicles. The measurements thus revealed that the integrity of liposomes was
well preserved even after incorporation with InP/ZnS quantum dots.

Figure 3.5 Particle size distributions of (a) liposomes and (b) InP/ZnS QD-liposomes.
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Figure 3.6 (a) Emission spectra, and (b) normalized graph of liposome encapsulated quantum
dots in PBS pH 7.2 buffer at various concentrations from 0 nM to500 nM of quantum dots.
The effect of quantum dot concentration on emission intensity of QD-liposomes was
studied and compared to that of fluorescein-liposomes (Figure 3.6). It was observed that the
emission intensity of QD-liposomes increased with an increase in concentrations of quantum
dots from 0 to 500 nM (Figure 3.6a) and the fluorescence intensity plotted as a function of QDs
concentration showed a linear regression (Figure 3.6b). On the other hand, the emission intensity
of fluorescein-liposomes increased with increase in concentration of fluorescein from 0-50 μM
and then decreased (Figure 3.6b insert). This behavior can be attributed to self-quenching of
fluorescein.
The photostability of InP/ZnS QD-liposomes was studied and compared with the MHDA
capped quantum dots and InP/ZnS quantum dots for 60 min. For demonstration of photostability,
all the samples were illuminated continuously with a mercury lamp of 60 W/cm2 for 1 hr. The
fluorescence intensity of the InP/ZnS QDs decreased by 57% of the initial intensity (Figure 3.7).
On the other hand fluorescent intensity of MHDA capped QDs and QD-liposomes decreased to
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30% and 27% of the initial intensities after 60 min of continuous illumination. This suggests that
the encapsulation of InP/ZnS QDs into liposomes further enhances the photostability of the
InP/ZnS quantum dots.

Figure 3.7 Photostability studies of lnP/ZnS quantum dots (♦), 16-mercaptohexadecanoic acid
(MHDA) coated InP/ZnS QDs (■), and liposome encapsulated InP/ZnS quantum dots (▲) in
PBS pH 7.2 buffer.
The effect of pH on the optical properties of InP/ZnS quantum dots encapsulated in
liposomes as demonstrated in Figure 3.8 showed that the PL intensity of the InP/ZnS quantum
dots was independent on the pH of the buffer. When changing the pH of the buffer from 4.2 to
11.2, less than 10% variation in the PL intensity of InP was observed as opposed to ~40%
variation in PL intensity of InP/ZnS coated with mercaptosuccinic acid reported by Yong et al.32
The bilayer surrounding the quantum dots is believed to have contributed to greater stability of
QD-liposomes when altering the pH from 4.2 to 11.2.
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Figure 3.8 InP/ZnS PL intensity dependence on pH.
3.5 Conclusions
For the first time InP/ZnS quantum dots were incorporated into liposomes, making the
InP/ZnS quantum dots water soluble and biocompatible. The structural characterization of
InP/ZnS quantum dots demonstrated well preserved integrity of liposomes even after
incorporation of InP/ZnS quantum dots. The photostability studies of InP/ZnS QD-liposomes
compared with the MHDA capped quantum dots and InP/ZnS quantum dots showed that indeed
encapsulation enhanced the photostability of the InP/ZnS quantum dots. The effect of pH on the
optical properties of InP/ZnS quantum dots showed < 10% variation in the PL intensity of InP as
opposed to ~40% variation in PL intensity of InP/ZnS coated with mercaptosuccinic acid
reported previously by Yong et al.32 The results show greater advantages of InP/ZnS QDliposomes over InP/ZnS quantum dots. The InP/ZnS-liposome complexes thus synthesized will
find a wide range of biological applications such as bioimaging, bioassays and immunoassays.
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Thus InP/ZnS-liposome complexes can aid as potential tools in identification and diagnosis of
several ailments associated with human pathology.
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Chapter 4
CdSe/ZnS quantum dot based immunoassay for simultaneous
detection of myocardial infarction biomarkers

4.1 Abstract
Myocardial infarction or heart attack is the leading cause of death worldwide for both
men and women. Sensitive and selective measurement of cardiac biomarkers is crucial in
assisting diagnosis of heart attack and in assessing the patients with nondiagnostic
electrocardiograms. Quantum dot based probes are receiving great attention for optical imaging
of cells and in bioassays as an alternative to conventional organic fluorophores due to their
unique size-dependent chemical and physical properties. In the current study quantum dot based
fluorescence immunoassay was developed for simultaneous detection of the cardiac biomarkers
troponin T and troponin I. A sandwich immunoassay was performed with capture antibodies
immobilized on a 96-well plate. After binding targeted biomarkers to capture antibodies,
detection antibodies conjugated to CdSe/ZnS quantum dots were then bound to the specific
biomarkers forming a sandwich complex. The results of the assay showed a clear dependence of
concentrations for both troponin T and I on the fluorescence emission of quantum dots that were
bound to the detection antibodies. The detection limit for both troponin T and troponin I was 0.1
pg/mL. No significant cross reactivity was seen between the antibodies and the antigens. The
multiplex detection method for screening of biomarkers is expected to yield a high throughput
diagnostic tool for heart attack.
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4.2 Introduction
Myocardial infarction (MI) or heart attack is the leading cause of death in both men and
women worldwide.1 Although long step have been taken to reduce the number of deaths, the
number of patients is still increasing.2, 3 Over several decades, the diagnosis of MI has been
based on the “two out of three” criteria as defined by World Health Organization, including
typical chest pain that lasts for more than 20 minutes, changes in electrocardiogram, and increase
in the serum level of creatine kinase-MB.4 The criteria for diagnosis was redefined recently, that
gave more importance to cardiac biomarkers especially troponins as they are more superior to
conventional measurement of CK-MB.5, 6 Troponin is a complex of three regulatory muscle
proteins troponin T (TnT), troponin I (TnI), and troponin C (TnC) that play crucial role in muscle
contraction. Cardiac and skeletal muscles contain both troponin T and I, however the amino acid
sequences of the proteins are different.7 Troponin C is shared by cardiac and skeletal muscles
and therefore do not exhibit cardiac specificity and is not used in the diagnosis of cardiac injury.
Under normal conditions troponin T and I levels are very low, but immediately after heart attack
the concentrations rise rapidly. The release kinetics is within 4-13 hour for both TnT and TnI
following myocardial damage.8, 9
For the first time in 1989 Katus et al described an enzyme immunoassay to detect
troponin T in human serum.10 The troponin T was bound to the solid phase by an affinity-purified
polyclonal antibody and detected by peroxidase labeled monoclonal antibody using one-step
sandwich assay. Later the same group developed a much more sensitive enzyme immunoassay,
using two troponin T-specific monoclonal antibodies with streptavidin-coated polystyrene tubes
as the solid phase.11 Recently Mayilo et al developed a homogenous immunoassay with gold
nanoparticles as fluorescence quenchers, using this method a detection limit of 0.7 ng/mL for
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cTnT was achieved.12 The first assay that demonstrated the potential diagnostic specificity of
troponin I quantification for myocardial infarction was developed by Cummins et al in 1983.13
Currently, several immunoassay methods are available commercially for the detection of
troponin I and troponin T separately, most of them are based on UV and some of them are based
on fluorescence.14-16 However, the current detection limits of troponin assays do not allow
demonstration of normal cardiac troponin levels in healthy controls.17 Thus lower detection
limits with improved assay sensitivity and precision are required to improve risk assessment.
Colloidal semiconductor nanoparticles or quantum dots (QDs) have emerged as a new
generation fluorescent labels in the two decades for optical imaging of cells, tissues and in
bioassays as alternatives to conventional organic fluorophores due to their unique optical
properties.18-25 QDs offer advantages like brightness, greater photostability, and broad excitation
wavelength range, size-tunable narrow and symmetric emission spectrum. More importantly,
regardless of the excitation wavelength QDs can be excited efficiently at any wavelength shorter
than the emission peak that will emit the same narrow, symmetric characteristic spectrum. This
unique property makes it possible to simultaneously detect different emission peaks when
different sizes of QDs are excited with a single wavelength. QDs have been used as fluorescent
labels in several applications including multicolor imaging of tissues26 and detection of toxins.27
The applications of QDs have also been extended for microorganism detection using multicolor
detection based immunoassay formats.28, 29 Previously it was shown that QDs has exhibited
superior photostability than traditional organic dyes in detection and has allowed dual color for
Cryptosporidium parvum and Giardia lamblia.30
In the current study a new method of CdSe/ZnS quantum dot based fluorescence
immunoassay has been developed for simultaneous detection of the cardiac biomarkers troponin
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T and troponin I. In the immunoassay the capture antibodies were immobilized on a 96-well
plate that were later bound to targeted biomarkers. A sandwich complex was formed after
detection antibodies conjugated to CdSe/ZnS quantum dots were bound to their specific
biomarkers. The results of the assay showed a clear dependence of troponins concentration on
the fluorescence emission of quantum dots attached to the detection antibodies. Detecting the
two biomarkers simultaneously is aimed to yield a high throughput diagnostic tool for heart
attack.
4.3 Experimental Methods
4.3.1 Materials and reagents. Technical grade (90%) trioctylphosphine oxide (TOPO),
technical grade (90%) trioctylphosphine (TOP), cadmium oxide (99.99%), selenium powder
(99.5%), lauric acid (98%), technical grade (90%) hexadecylamine (HDA), diethyl zinc (Zn(Et)2)
solution 1.0 M in heptane, hexamethyldisilathiane ((TMS)2S), methanol anhydrous (99.8%),
chloroform (99.5%), 16-mercaptohexadecanoic acid (MHDA), tetramethylammonium hydroxide
pentahydrate, Tween 20, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC),
sulfo-N-hydroxysulfosuccunimide (sulfo-NHS), and bovine serum albumin (BSA) were
purchased from Sigma Aldrich. Amine reactive maleic anhydride activated 96 well plates, and
super block blocking buffer were purchased from Thermo Scientific. Mouse monoclonal cardiac
troponin T antibody (1C11), mouse monoclonal cardiac troponin I antibody (M18), cardiac
troponin T protein, cardiac troponin I protein, and creatine kinase-MB protein were purchased
from Abcam. Mouse monoclonal cardiac troponin T antibody (7e7), and mouse monoclonal
cardiac troponin I antibody (MF4) were purchased from Santa Cruz biotechnology.
4.3.2 Synthesis of TOPO capped luminescent quantum dots. TOPO-capped CdSe/ZnS
quantum dots were prepared following a method first proposed by Peng et al31 with a slight
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modification.32 Briefly, 12-13 mg of cadmium oxide and 160-180 mg of lauric acid were mixed
under nitrogen atmosphere. The mixture was heated in a 100 mL three neck flask to slightly
above 180°C to fully dissolve the cadmium oxide (clear solution). Then, 2 g of TOPO and 2 g
HDA were added to the solution with constant stirring. Temperature was raised to 280°C before
being cooled down slowly. Upon reaching the desirable temperature 80 mg selenium powder
dissolved in 2 mL solution of TOP was rapidly injected into the solution under vigorous stirring.
For shell coating, a 2 mL TOP solution containing 250 μL (TMS)2S and 1 mL Zn(Et)2 was
injected drop-wise into the solution. The reaction mixture was kept at 180°C for one hour before
it was cooled to room temperature and washed three times with methanol, centrifuged at 4000
rpm for 10 minutes each, and redispersed in chloroform. The concentration of this solution was
found to be 1 μM. The solution was stored at room temperature.
4.3.3 Synthesis of mercaptohexadecanoic acid (MHDA) coated quantum dots. 16mercaptohexadecanoic acid coated quantum dots were prepared following a modified procedure
developed by Bawendi33 for the synthesis of lipoic acid capped CdSe/ZnS core-shell quantum
dots. 25 mg of MHDA was heated up to 70-80°C to dissolve and 3 mL of 1 μM TOPO coated
quantum dots and 3 mL of chloroform were added and stirred for 2-3 hours at 50-60°C. Then 6
mL of DI water containing tetramethylammonium hydroxide pentahydrate was added to the
mixture and stirred for another half hour at room temperature and then allowed to settle down for
few minutes. This resulted in a two-phase mixture with the aqueous MHDA coated quantum dots
layer above the organic chloroform layer. The aqueous layer was collected and centrifuged
several times to remove TOP/TOPO until clear solution was seen. Then the clear suspensions
were collected and spin dialyzed two times with a cutoff molecular weight of 30000 Da to
remove the excess MHDA. In each spin dialysis cycle, the sample was centrifuged at 3000 rpm
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for 20 minutes and washed with DI water. MHDA coated quantum dots were kept at 4°C in DI
water until used.
4.3.4 Conjugation of MHDA coated quantum dots with detection antibodies. Conjugation of
antibodies onto MHDA coated CdSe/ZnS quantum dots was achieved using the classic EDC
coupling reaction of COOH groups on the surfaces of the MHDA coated quantum dots and NH2
groups of the antibody. Typically, 0.1 mL of MHDA coated CdSe/ZnS quantum dots, 20 μL of
30 mg/mL EDC and 20 μL of 30 mg/mL sulfo-NHS were added into a 1.5 mL tube. The mixture
was vortexed for 15-20 min at room temperature to fully activate free carboxylic acid groups on
the quantum dots. In this step, semi stable amine-reactive NHS-ester could be synthesized by the
esterification of the activated carboxylic acid groups on the QDs and hydroxyl groups on the
sulfo-NHS. 100 μL of detection antibodies was added into the system and was vortexed for at
least 2 h. The unreacted antibody molecules were removed from the media by centrifugal
concentrators (cutoff molecular weight: 100 kD). Quantum dots and antibodies were connected
through strong covalent bonds. The final products were recollected into 10 mM PBS pH 7.4
buffer containing 0.1% BSA and kept at 4°C. The purified quantum dot-antibody conjugates
were ready to be used to detect the target antigens.
4.3.5 Individual fluoroimmunoassays. Fluoroimmunoassays were essentially performed as
previously described.34, 35 Wells of clear microtiter plates were washed three times with 200 μL
of wash buffer (PBS pH 8.0 buffer containing 0.05% Tween 20). Then, 100 μL of 25 μg/mL
concentration of capturing antibodies dissolved in 10 mM PBS pH 7.4 buffer were added to the
plate and incubated overnight at room temperature. The capture solution was discarded and the
plates were blocked using 200 μL of super block blocking buffer and incubated for one hour at
room temperature. This quenches the remaining reactive maleic anhydride groups and also
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blocks left over open sites on the plate surface. The blocking buffer was discarded and the plate
washed three times with wash buffer. Different concentrations of 100 μL, troponin T or troponin
I antigens were added to plate wells and incubated for 1 hour at room temperature. Plate wells
were washed three times with wash buffer to remove the unbound antigens. 100 μL of the
detection antibodies conjugated to different colored quantum dots were added to the plate wells
and incubated for one hour at room temperature and the unbound antibodies were removed by
washing three times with the wash buffer.
4.3.6 Multiplexing fluoroimmunoassays. Wells of clear microtiter plates were washed three
times with 200 μL of wash buffer (PBS pH 8.0 buffer containing 0.05% Tween 20). Then, 50 μL
each of 50 μg/mL concentration of capturing antibodies dissolved in 10 mM PBS pH 7.4 buffer
were added to the plate and incubated overnight at room temperature. The capture solution was
discarded and the plates were blocked using 200 μL of super block blocking buffer and incubated
for one hour at room temperature. The blocking buffer was discarded and the plate washed three
times with wash buffer. Different concentrations of 50 μL of troponin T and troponin I antigens
were added to plate wells and incubated for 1 hour at room temperature. Plate wells were washed
three times with wash buffer to remove the unbound antigens. 50 μL each of the detection
antibodies conjugated to two different colored quantum dots were added to the plate wells and
incubated for one hour at room temperature and the unbound antibodies were removed by
washing three times with the wash buffer.
4.3.7 Fluorescence spectroscopy measurements. Excitation and emission spectra were
measured using a spectrofluorometer (SpectraMax M2, Molecular Devices) equipped with a 75
W continuous xenon arc lamp as a light source. All the samples were excited at 400 nm.
Emission scans were measured from 450-750 nm.
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4.3.8 Digital fluorescence imaging microscopy. Luminescence images were obtained using a
digital inverted fluorescence microscope (Olympus IX71) equipped with a 100 W mercury lamp
as a light source. The fluorescence images were collected via a 20 X microscope objective with
numerical aperture = 0.5. A filter cube containing a 380±20 nm band-pass excitation filter, a 425
nm dichroic mirror, and a 450 nm long pass emission filter was used to ensure spectral imaging
purity. Digital point controller (DP72) was used for digital imaging. An exposure time of 100
ms was typically used to acquire the fluorescence images.
4.4 Results and Discussion
TOPO coating of the luminescent CdSe/ZnS quantum dots were first replaced with 16mercaptohexadecanoic acid using ligand exchange method. The optical properties of the
quantum dots were well preserved even after ligand exchange with MHDA. Antibody conjugated
quantum dots are often used for biological labeling and staining.36 Covalent conjugation of
quantum dots with biomolecules is most commonly based on cross-linking reactions between
amine and carboxylic acid groups, between amine and sulfhydryl groups, or between aldehyde
and hydrazide functional groups. Among these methods the amine-carboxylic acid cross-linking
method is the more prominent one as most proteins contain primary amine and carboxylic acid
groups and do not need chemical modifications before conjugation. However, some instability of
the QDs might occur with this technique when chemically modifying the QDs stabilizer cap and
the cross-reaction of the QD-COOH groups with multiple amines on biomolecules.37 To
overcome this problem, Hu et al studied the key factors influencing the chemical stability of QDs
and demonstrated a QD-based bioconjugating strategy.38 In the current work EDC coupling of
quantum dots with the different detection antibodies were achieved following their method.
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Figure 4.1 Fluorescence intensities of two different colored quantum dots (dotted lines) and QDdetection antibody conjugates (continuous lines) at the same concentration of QDs.
Figure 4.1 shows the emission spectra of 545 and 615 nm quantum dots before and after
conjugation with the detection antibodies of troponin T and troponin I respectively. Quantum
dot-antibody conjugates have shown slight enhancement in the emission intensity of the QDs
while retaining optical properties of the quantum dots. This enhancement in intensity might be
due to presence of antibodies layer on the surface of quantum dots. The stability of the QDantibody conjugates stored at 4°C temperature was studied over a period of 28 days. The QDantibody conjugates have shown very good stability when stored in 10 mM PBS pH 7.4 buffer
containing 0.1% BSA demonstrated by 5% decrease in the initial fluorescence intensity (Figure
4.2).
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Figure 4.2 Normalized fluorescence intensity of QD-antibody conjugates at different days.
The immunoreaction was performed using sandwich type procedure. Scheme 4.1 shows
the quantum dot based fluoroimmunoassay protocol used in this work. At first the capture
antibodies were immobilized on the well plate followed by the addition of blocking buffer to
block the nonspecific binding sites. The antigens, troponin T or/and troponin I were added that
bind to their corresponding capture antibodies. The unbound antigens were removed by washing.
Finally the detection antibodies conjugated to 545 or/and 615 nm quantum dots were added that
bind to the corresponding antigens forming a sandwich immunocomplex. The fluorescence
intensities of the quantum dots attached to the immunocomplex were measured for the
quantification of the antigens troponin T and troponin I.
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Scheme 4.1 Schematic representation of QD based fluoroimmunoassay principle.
4.4.1 Optimization of experimental conditions. The immobilization of the capturing antibody
on well plate is crucial since it is the first step in the immunoassay system. The concentration of
capture antibody solution in the immobilization determines the amount of antibody immobilized
on the well plate. Serial concentrations of antibody solution were tested in order to investigate
the maximum loading of the capturing antibody. The fluorescence intensity of the quantum dots
present in the immunocomplex was increased with the capture antibody concentrations from 0 to
25 μg/mL. Further increase of antibody concentration in the immobilization did not improve the
results (Figure 4.3).
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Figure 4.3 Immobilization of capturing antibody (anti-TnT) on 96-well plate at 10 ng/mL of
troponin T protein and 60 minutes of incubation time. λex: 400 nm.

Figure 4.4 Effect of incubation time on capture of antigen on 96-well plate at 25 μg/mL of
capture antibody and 10 ng/mL of troponin T protein concentration. λex: 400 nm
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Next, the effect of incubation time for capturing antigen by the capturing antibody on the
plate was also optimized. As shown in Figure 4.4 the fluorescence intensity was increased with
increasing the incubation time up to 60 minutes and further increasing in time did not show any
increase in the emission intensity indicating that 60 minutes incubation time is optimal. Further
incubation with longer time may destroy the activity of the antigen and might exert an effect on
the reorganization of quantum dot conjugated detection antibodies with antigen.
4.4.2 Individual Assays. For each of the two antigens single analyte assays were performed
initially to ensure the usefulness of QD-antibody pairs in a multicolor multianalyte study. In
these assays, only the appropriate capture antibody and individual antigens were applied to wells,
and the emission intensities of single colored QDs that are conjugated to detection antibodies
will be measured for quantification.

Figure 4.5 a) Emission spectra of 545 nm emitting QDs in the immunocomplex at different
concentrations of troponin T b) relationship between troponin T concentration and the
fluorescence intensity of the QDs.
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Figure 4.5a shows the fluorescence emission spectra of 545 nm emitting quantum dots
that are conjugated to anti-TnT antibodies. The emission intensity increased with increasing
concentration of troponin T from 0 to 10 ng/mL. There is a linear-log relationship between the
enhanced intensity of quantum dots and the concentration of troponin T (Figure 4.5b). The
detection limit is as low as 0.1 pg/mL for the troponin T which is the best detection limit
achieved so far that allows the demonstration of the troponin T levels even in the healthy normal
controls.

Figure 4.6 a) Emission spectra of 615 nm emitting QDs in the immunocomplex at different
concentrations of troponin I b) relationship between troponin I concentration and the
fluorescence intensity of the QDs.
Similarly Figure 4.6a is the fluorescence emission spectra of 615 nm emitting quantum
dots that are conjugated to anti-TnI antibodies. Similar to troponin T the emission intensity
increased with increasing concentrations of troponin I. Figure 4.6b shows the concentration
dependence of the emission intensity of the quantum dots. Similar to troponin T the detection
limit was as low as 0.1 pg/mL for the troponin I.
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In principle, the specificity of the method depends mainly upon the specificity of the
monoclonal antibodies. Nevertheless, the selectivity of the method is also affected by the nonspecific binding on well plate, the properties of the proteins, and the nature of the fluorescence
labels. The specificity of the method was studied to check for any cross reactivity between the
antigens and antibodies. The experiments involved the addition of anti-troponin T capturing
antibody to the well plate followed by the addition of four different antigens 1% BSA, troponin
T, CK-MB, and Troponin I. The anti-troponin T detection antibodies conjugated to 545 nm
emitting QDs were added to the well plate. The signals of the quantum dots for this experiment
are represented as green bars in figure 4.7. Similar procedure was performed for troponin I and
the signals from the 615 nm emitting QDs are represented as red bars in the figure 4.7. Greater
signal intensities were observed for the specific antigen-antibody conjugates while there is no
cross reactivity of the antibodies with the other antigens demonstrating the specificity of the
method.

Figure 4.7 The selectivity of the quantum dot based fluoroimmunoassay method.
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4.4.3 Multiplexing Assay. A mixture of troponin T and I capture antibodies were coated on the
plate. After binding of troponin T and I antigens to capture antibodies, the detection antibodies
conjugated to CdSe/ZnS quantum dots were then bound to the specific biomarkers. The emission
spectra of both 545 nm and 615 nm QDs are showed in figure 4.8. The fluorescence intensities
increased with increasing concentrations of troponin T and troponin I indicating dependence of
the QDs signals on the concentrations of the corresponding antigens.

Figure 4.8 Emission spectra of 545 nm and 615 nm emitting QDs that are bound to different
concentrations of troponin T and troponin I respectively.
4.5 Conclusions
In summary a new protocol has been developed for quantum dot based
fluoroimmunoassay for simultaneous detection of troponin T and troponin I. MHDA coated
quantum dots conjugated to detection antibodies have demonstrated greater stability for extended
period. The experimental conditions optimized to perform individual assays for the detection of
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troponin T and troponin I have achieved a detection limit of 0.1 pg/mL. The detection limits
allow the diagnosis of troponin levels in healthy controls. The method was highly specific for the
biomarkers troponin T and I with no observed cross reactivity. The multiplex assay was
successful in detection of two biomarkers simultaneously. The experimental results support the
success of the method in controlled aqueous (buffer) solution. Therefore to further establish the
applicability of the method in real samples the method has to be verified in PBS buffer with high
salt concentrations and eventually in serum samples. Despite success in developing new method
for diagnosis of biomarkers the method also needs improvement in terms of fast response time as
increased times for onsite analysis of the biomarkers will delay the patient diagnosis and
treatment. The QD based fluoroimmunoassay developed will thus yield a high throughput
diagnostic tool for heart attack.
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Chapter 5
Detection of atherosclerosis biomarkers using a CdSe/ZnS quantum
dot based fluorescence immunoassay

5.1 Abstract
Atherosclerosis is a chronic inflammatory vascular disease that involves several events at
each step from early fatty streak lesions to highly dangerous rupture-prone plaque. Plaque
rupture can lead to debilitating or deadly events such as heart attack and stroke. Simultaneous
detection of plasma markers of inflammation and plaque instability will improve assessment of
risk for vascular events. The current study is aimed to develop a QD based fluorescence
immunoassay for simultaneous detection of plasma markers monocyte chemoattractant protein-1,
interleukin 15, and interleukin 18 involved in fatty streak and plaque instability. As preliminary
work experimental conditions were optimized for detection of MCP-1 and IL-15 achieving
detection limits of 100 pg/mL and 10 pg/mL respectively. The detection limits are comparable to
currently reported methods. Further a new approach was proposed to incorporate QDs into silica
beads before binding to the detection antibodies to further improve the detection limits. The
future prospects for this work are optimization of experimental conditions for third biomarker
IL-18 and multiplexing the three biomarkers for simultaneous detection. This study thus provides
preliminary results to yield a reliable method for simultaneous and rapid detection of multiple
atherosclerosis biomarkers for early diagnosis.
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5.2 Introduction
Atherosclerosis is a chronic inflammatory vascular disease that involves several events at
each step from early fatty streak lesions to highly dangerous rupture-prone plaque.1 The principal
mechanisms of myocardial and cerebral infarctions involve disruption of atherosclerotic plaques
and the subsequent formation of thrombus or blood clot.2 Atherosclerotic plaques are classified
into two types, stable and susceptible, of which the latter one is more vulnerable to rupture.3 A
vulnerable plaque is characterized by a large lipid-rich core, a thin fibrous cap, and penetration
by inflammatory cells, such as macrophages.4 Thus, to provide the information for early
treatment and risk assessment the detection of vulnerable plaques becomes clinically important.
Detection of vulnerable atherosclerotic plaques involved several imaging techniques including
conventional X-ray contrast angiography, to detect morphological characteristics such as
stenosis. However, X-ray contrast angiography was not successful in determining whether a
plaque is stable or vulnerable as both types of plaques cause stenosis.5 In addition to
conventional methods other approaches involving the use of magnetic resonance imaging (MRI)
have also been developed. These approaches have been successful in discriminating lipid cores,
fibrous caps, and hemorrhaged lesions.6-10 To directly image an atheroma intravascular ultra
sonography technique are also currently being used.11-13 Computed tomography,14 and positron
emission tomography15 are the other new techniques used for diagnosis. However all these new
approaches do not provide information about presence of inflammation which is indicative of a
vulnerable plaque though the images provide morphological characteristics of the atheroma.
Recent research have repeatedly shown the use of biomarkers in different stages of
atherosclerosis like molecular proinflammatory biomarkers, plaque destabilization and plaque
rupture biomarkers to predict future cardiovascular prevalence not only in healthy individuals,
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but also in patients with acute coronary syndrome.16 Therefore testing patients for several of
these biomarkers will provide important information useful for predicting future incidence of
atherosclerosis. In the previous chapter quantum dots based fluoroimmunoassay method has been
developed for simultaneous detection of heart attack biomarkers, troponin T and troponin I that
achieved a detection limit of 0.1 pg/mL. The multiplex assay was able to detect two biomarkers
simultaneously that will yield a high throughput diagnostic tool for heart attack.
The current study aims at development of QD based fluorescence immunoassay for
simultaneous detection of three atherosclerosis markers monocyte chemoattractant protein-1
(MCP-1), interleukin 15 (IL-15), and interleukin 18 (IL-18) that play significant role in two
important stages of atherosclerosis, fatty streaks and plaque destabilization. MCP-1 is an
important chemokine whose expression increases in atherosclerotic lesions, particularly in
macrophage-rich areas.17, 18 Interleukin 15 is a biomarker associated with atherosclerosis whose
expression is found exclusively in fibrolipid and lipid-rich plaques in complex foam cells.19, 20
IL-18, is another biomarker and increased expression of IL-18 is seen in lesions prone to
rupture, and is localized mainly in plaque macrophages.21, 22 Simultaneous detection of plasma
markers of inflammation and plaque instability will improve risk assessment for vascular events.
5.3 Experimental Methods
5.3.1 Materials and reagents. Technical grade (90%) trioctylphosphine oxide (TOPO),
technical grade (90%) trioctylphosphine (TOP), cadmium oxide (99.99%), selenium powder
(99.5%), lauric acid (98%), technical grade (90%) hexadecylamine (HDA), diethyl zinc (Zn(Et)2)
solution 1.0 M in heptane, hexamethyldisilathiane ((TMS)2S), methanol anhydrous (99.8%),
chloroform (99.5%), 16-mercaptohexadecanoic acid (MHDA), tetramethylammonium hydroxide
pentahydrate, Tween 20, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC),
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sulfo-N-hydroxysulfosuccunimide (sulfo-NHS), and bovine serum albumin were purchased from
Sigma Aldrich. Amine reactive maleic anhydride activated 96 well plates, and super block
blocking buffer were purchased from Thermo Scientific. Mouse monoclonal IL-15 antibody,
rabbit polyclonal IL-15 antibody, IL-15 protein, mouse monoclonal MCP-1 antibody, rabbit
polyclonal MCP-1 antibody, MCP-1 protein were purchased from Abcam.
5.3.2 Synthesis of TOPO capped luminescent quantum dots. TOPO-capped CdSe/ZnS
quantum dots were prepared following a method first proposed by Peng et al23 with a slight
modification.24 Briefly, 12-13 mg of cadmium oxide and 160-180 mg of lauric acid were mixed
under nitrogen atmosphere. The mixture was heated in a 100 mL three neck flask to slightly
above 180°C to fully dissolve the cadmium oxide (clear solution). Then, 2 g of TOPO and 2 g
HDA were added to the solution with constant stirring. Temperature was raised to 280°C before
being cooled down slowly. Upon reaching the desirable temperature 80 mg selenium powder
dissolved in 2 mL solution of TOP was rapidly injected into the solution under vigorous stirring.
For shell coating, a 2 mL TOP solution containing 250 μL (TMS)2S and 1 mL Zn(Et)2 was
injected drop-wise into the solution. The reaction mixture was kept at 180°C for one hour before
it was cooled to room temperature, washed three times with methanol, centrifuged at 4000 rpm
for 10 minutes each, and redispersed in chloroform. The concentration of this solution was found
to be 1 μM. The solution was stored at room temperature.
5.3.3 Synthesis of mercaptohexadecanoic acid (MHDA) coated quantum dots. 16mercaptohexadecanoic acid coated quantum dots were prepared following a modified procedure
developed by Bawendi25 for the synthesis of lipoic acid capped CdSe/ZnS core-shell quantum
dots. 25 mg of MHDA was heated up to 70-80°C to dissolve and 3 mL of 1 μM TOPO coated
quantum dots and 3 mL of chloroform were added and stirred for 2-3 hours at 50-60°C. Then 6
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mL of DI water containing tetramethylammonium hydroxide pentahydrate was added to the
mixture and stirred for another half hour at room temperature and then allowed to settle down for
few minutes. This resulted in a two-phase mixture with the aqueous MHDA coated quantum dots
layer above the organic chloroform layer. The aqueous layer was collected and centrifuged
several times to remove TOP/TOPO until clear solution was seen. Then the clear suspensions
were collected and spin dialyzed two times with a cutoff molecular weight of 30000 Da to
remove the excess MHDA. In each spin dialysis cycle, the sample was centrifuged at 3000 rpm
for 20 minutes and washed with DI water. MHDA coated quantum dots were kept at 4°C in DI
water until used.
5.3.4 Conjugation of MHDA coated quantum dots with detection antibodies. Conjugation of
antibodies onto MHDA coated CdSe/ZnS quantum dots was achieved using the classic EDC
coupling reaction of COOH groups on the surfaces of the MHDA coated quantum dots and NH2
groups of the antibody. Typically, 0.1 mL of MHDA coated CdSe/ZnS quantum dots, 20 μL of
30 mg/mL EDC and 20 μL of 30 mg/mL sulfo-NHS were added into a 1.5 mL tube. The mixture
was vortexed for 15-20 min at room temperature to fully activate free carboxylic acid groups on
the quantum dots. In this step, semi stable amine-reactive NHS-ester could be synthesized by the
esterification of the activated carboxylic acid groups on the QDs and hydroxyl groups on the
sulfo-NHS. 100 μL of detection antibodies was added into the system and was vortexed for at
least 2 h. The unreacted antibody molecules were removed from the media by centrifugal
concentrators (cutoff molecular weight: 100 kD). Quantum dots and antibodies were connected
through strong covalent bonds. The final products were recollected into 10 mM PBS pH 7.4
buffer containing 0.1% BSA and kept at 4°C. The purified quantum dot-antibody conjugates
were ready to be used to detect the target antigens.
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5.3.5 Individual fluoroimmunoassays. Fluoroimmunoassays were essentially performed as
previously described. 26, 27 Wells of clear microtiter plates were washed three times with 200 μL
of wash buffer (PBS pH 8.0 buffer containing 0.05% Tween 20). Then, 50 μL of different
concentration of capturing antibodies dissolved in 10 mM PBS pH 7.4 buffer were added to the
plate and incubated overnight at room temperature. The capture solution was discarded and the
plates were blocked using 200 μL of super block blocking buffer and incubated for one hour at
room temperature. This quenches the remaining reactive maleic anhydride groups and also
blocks left over open sites on the plate surface. The blocking buffer was discarded and the plate
washed three times with wash buffer. Different concentrations of 50 μL of IL-15 or MCP-1
antigens were added to plate wells and incubated for 1 hour at room temperature. Plate wells
were washed three times with wash buffer to remove the unbound antigens. 50 μL of the
detection antibodies conjugated to different colored quantum dots were added to the plate wells
and incubated for one hour at room temperature and the unbound antibodies were removed by
washing three times with the wash buffer.
5.3.6 Fluorescence spectroscopy measurements. Excitation and emission spectra were
measured using a spectrofluorometer (SpectraMax M2, Molecular Devices) equipped with a 75
W continuous xenon arc lamp as a light source. All the samples were excited at 400 nm.
Emission scans were measured from 450-750 nm.
5.3.7 Digital fluorescence imaging microscopy. Luminescence images were obtained using a
digital inverted fluorescence microscope (Olympus IX71) equipped with a 100 W mercury lamp
as a light source. The fluorescence images were collected via a 20 X microscope objective with
numerical aperture = 0.5. A filter cube containing a 380±20 nm band-pass excitation filter, a 425
nm dichroic mirror, and a 450 nm long pass emission filter was used to ensure spectral imaging

91

purity. Digital point controller (DP72) was used for digital imaging. An exposure time of 100
ms was typically used to acquire the fluorescence images.
5.4 Results and Discussion
A similar method developed in chapter 4 was used to detect atherosclerosis biomarkers.
16-mercaptohexadecanoic acid was used to replace TOPO coating of the luminescent CdSe/ZnS
quantum dots to make them water soluble and biocompatible. Figure 5.1 shows the emission
spectra and normalized emission spectra of TOPO coated quantum dots and MHDA coated
quantum dots respectively. The optical properties of the quantum dots were well preserved even
after ligand exchange with MHDA as shown in Figure 5.1b.

Figure 5.1 (a) Emission and (b) normalized emission spectra of TOPO coated quantum dots (red
line) and MHDA coated quantum dots (green line) at same concentration of quantum dots.
Antibody conjugated quantum dots are often used for biological labeling and staining.28
The EDC coupling reaction between a carboxylic group and an amine group is the classic
reaction for bioconjugation of biomolecules (Scheme 5.1). EDC reacts with the carboxylic
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groups on the MHDA coated QDs and forms an amine reactive O-acylisourea intermediate. This
intermediate is very susceptible to hydrolysis and hence is unstable and short lived. The desired
coupling cannot occur if the targeted amine does not find the active carboxylate before
hydrolysis and this is overcome by adding the sulfo-NHS. The advantage of addition of sulfoNHS to the EDC reaction was to increase the stability of the active intermediate by converting it
to amine reactive sulfo-NHS ester intermediate which reacts with the attacking amine from the
antibodies. Excess reagent and isourea are formed as byproducts of the cross-linking reaction
that are water-soluble and can be easily removed by dialysis or filtration.29 The QD-antibody
bioconjugates were found to be stable and their brightness remained the same for a long time
when stored in a refrigerator at 4°C in the PBS pH 7.4 buffer solution containing 0.1% BSA.

Scheme 5.1 Schematic representation of EDC/NHS coupling chemistry.
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The immunoreaction was performed using sandwich assay. The workflow of quantum dot
based fluoroimmunoassay is depicted in scheme 5.1. First the capture antibodies were
immobilized on the well plate followed by blocking buffer to block the nonspecific binding. The
antigens IL-15 or/and MCP-1 were added that bind to the corresponding capture antibodies and
the unbound antigens were removed by washing. Finally the detection antibodies conjugated to
545nm or/and 615 nm quantum dots were added that bind to the corresponding antigens forming
a sandwich immunocomplex. The fluorescence intensities of the quantum dots attached to the
immunocomplex were measured for the quantification of the antigens IL-15 and MCP-1.

Scheme 5.2 Schematic representation of QD based fluoroimmunoassay principle.
The experimental conditions were initially optimized for the detection of two biomarkers
IL-15 and MCP-1. The effect of incubation time was optimized for capturing antigen by the
capturing antibody on the plate. The antigens were added at a concentration of 1 ng/mL and
incubated at 37oC for different time intervals. The fluorescence intensity increased with
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increasing the incubation time for up to 2 hours and further increasing in time did not show any
increase in the emission intensity suggesting 2 hours as optimal incubation time at 37oC. Further
incubation for longer periods may destroy the activity of the antigen and effect reorganization of
quantum dots conjugated detection antibodies with antigen.

.
Figure 5.2 Effect of incubation time on capture of antigen on 96-well plate at 25 μg/mL of
capture antibodies and 1 ng/mL of IL-15 (green) and MCP-1 protein (red) concentration. λex:
400nm.
The immobilization of the capturing antibody on well plate is crucial since it is the first
step in the immunoassay. The concentration of capture antibody solution in the immobilization
determines the amount of antibody immobilized on the well plate. Serial concentrations of
antibody solution from 0 to 50 μg/mL were tested in order to investigate the maximum loading
of the capturing antibody. The fluorescence intensity of the quantum dots present in the
immunocomplex increased with the capture antibody concentrations from 0 to 50 μg/mL for IL-

95

15 and from 0 to 10 μg/mL for MCP-1. Further increase in antibody concentration for the
immobilization did not improve the previously observed fluorescence intensities (Figure 5.3).

Figure 5.3 Immobilization of capturing antibodies on 96-well plate at 1 ng/mL of IL-15 (green)
and MCP-1 protein (red) and 60 minutes of incubation time. λex: 400 nm.
Individual analyte assays were done for each of the two antigens, IL-15 and MCP-1 to
ensure the use of QD-antibody pairs in a multicolor multianalyte study. In these assays, the
appropriate capture antibody and individual antigens were applied to wells, and the emission
intensities of single colored QDs that are conjugated to detection antibodies were measured for
quantification. Figure 5.4a shows the fluorescence emission spectra of 545 nm emitting quantum
dots that are conjugated to anti-IL15 antibodies. The emission intensity increased with increasing
concentrations of troponin T from 0 to 10 ng/mL. There is a linear-log relationship between the
enhanced intensity of quantum dots and the concentrations of IL-15 (Figure 5.4b). It was
possible to detect as low as 10 pg/mL for IL-15.
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Figure 5.4 a) Emission spectra of 545 nm emitting QDs in the immunocomplex at different
concentrations of IL-15 protein b) relationship between IL-15 concentration and the fluorescence
intensity of the QDs.

Figure 5.5 a) Emission spectra of 615 nm emitting QDs in the immunocomplex at different
concentrations of MCP-1 b) relationship between MCP-1 concentration and the fluorescence
intensity of the QDs.
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Similarly, Figure 5.5a is the fluorescence emission spectra of 615 nm emitting quantum
dots that are conjugated to anti-MCP-1 antibodies. Similar to IL-15 the emission intensity
increased with increasing concentrations of troponin I. Figure 5.5b shows the concentration
dependence of the emission intensity of the quantum dots. The detection limit was found to be
100 pg/mL for the MCP-1. The specificity of the method was studied to check for any cross
reactivity between the antigens and antibodies. The experiments involved the addition of antiIL15 capturing antibody to the well plate followed by the addition of different antigens 1%
bovine serum albumin (BSA), IL-15, and MCP-1. The anti-IL15 detection antibodies conjugated
to 545 nm emitting QDs were added to the well plate. The signals of the quantum dots for this
experiment are represented as green bars in Figure 5.6. Similar procedure was performed for
MCP-1 and the signals from the 615 nm emitting QDs are represented as red bars in the Figure
5.6. Greater signal intensities were observed for the specific antigen-antibody conjugates while
there is no significant cross reactivity of the antibodies with the other antigens demonstrating the
specificity of the method.

Figure 5.6 The selectivity of the quantum dot based fluoroimmunoassay method.
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The detection limits achieved in this work for the biomarkers of atherosclerosis though
were not the best but are comparable to the currently available methods. This can be attributed to
the low binding affinity of antigen-antibody pairs used in this method. Therefore a new approach
was proposed to improve the detection limits by incorporating TOPO coated QDs into silica
beads before binding to the detection antibodies (Scheme 5.3). Incorporation of large number of
QDs into a single silica bead will not only improve signal intensity but also will help improve
results even with low binding affinity antigen-antibody pairs. Furthermore, to complete the study
optimization of IL-18 and multiplexing of the assay have to be done for simultaneous detection
of the biomarkers. Also the applicability of the method in real samples collected from patients
has to be established.

Scheme 5.3 Schematic representation of QDs incorporated silica bead based fluoroimmunoassay
principle.
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5.5 Conclusions
The overall goal of the current study is to develop quantum dot based fluoroimmunoassay
for simultaneous detection of three plasma markers MCP-1, IL-15, and IL-18. Current work only
shows the optimized experimental conditions to perform individual assays for the detection of
MCP-1 and IL-15. The methods achieved a detection limit of 10 pg/mL for IL-15 and 100 pg/mL
for MCP-1 respectively. The inability to achieve better detection limits was attributed to low
binding affinity between the antigen-antibody pairs used in this method. Furthermore, to
complete the study optimization of IL-18 needs to be done to multiplex the assay for
simultaneous detection of these biomarkers. In addition a new approach was proposed to
improve the detection limits of MCP-1, IL-15 including IL-18 utilizing incorporation of quantum
dots into silica beads that is expected to increase the sensitivity of the method. The multiplex
assay able to detect three biomarkers simultaneously will be a high throughput diagnostic tool for
atherosclerosis. Also the applicability of the method in real samples collected from patients has
to be established. Despite the limitations the preliminary results are encouraging to develop
reliable method that will see light in the diagnose of atherosclerosis.
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Chapter 6

Summary and Conclusions
Luminescent quantum dots (QDs) have emerged as alternative fluorescent probes over
the last two decades in several biological and biomedical fields. They exhibit unique photophysical properties, such as broad absorption spectra with narrow and symmetrical emission
peaks, high quantum yield, high photostability, and size dependent luminescence. This
dissertation focused on development of quantum dot based bioassays for real time monitoring of
enzyme activity and simultaneous detection of several biomarkers.
Recently many research labs have developed quantum dot based fluorescence resonance
energy transfer (FRET)-based assays.1-3 Chang et al developed solution based FRET assays
using QDs as donors and gold nanoparticles (AuNPs) as acceptors for proteolytic activity
measurements.4 Shi et al from our lab have covalently linked molecular fluorescent acceptors to
the surface of single quantum dots and used the FRET probes for real-time monitoring of
protease activity in solution.3 Most of the developed quantum dot based FRET assays have
measured the proteolytic activity. In this study, a quantum dot based FRET assay was employed
for lipase activity measurements. The liposome encapsulated quantum dot based fluorescence
resonance energy transfer probes were synthesized and characterized to monitor the enzymatic
activity of phospholipase A2. The unique feature of this work is the platform, quantum dot
containing liposomes that can be prepared using commercially available substrates. Since the
quantum dots are not attached covalently to the phospholipids they do not affect the enzyme
activity of phospholipase A2. The phospholipid bilayer in QD-liposomes was also labeled with
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acyl NBD fluorophores. The application of molecular fluorophores as acceptors allows
ratiometric measurement to monitor FRET that results in real time changes in quantum dot and
fluorescent acceptor emission peaks. The addition of phospholipase A2 to QD-liposomes showed
changes in FRET signals due to cleavage of SN2-acyl bond and release of NBD fluorophores
from the membrane. The NBD molecules are hydrophilic in nature and move away from the
hydrophobic bilayers following PLA2 enzyme cleavage. The changes in FRET signals were
found to be phospholipase A2 concentration dependent. The QD based FRET probes were able to
detect the enzyme activity as low as 0.0075 U/ml (PLA2 = 1500 U/mg) in 30 min at room
temperature which is the best detection limit attained so far in comparison to commercially
available kits with detection limits up to 0.05 U/mL. Further the FRET probes were also used to
screen the inhibition efficiencies of two phospholipase A2 inhibitors 1-hexadecyl-3(trifluoroethyl)-sn-glycero-2-phosphomethanol and 3(4octadecyl)benzoylacrylic acid. QD based
FRET probes allow for multiplexing and screening large number of inhibitors simultaneously.
The method is also suitable for both kinetic analysis and large-scale screening using automated
readers for 96-well plates.
Despite several advantages offered by CdSe/ZnS QDs, replacement of organic
fluorophores is limited due to cytotoxicity associated with the individual ions present in the
quantum dots.5, 6 Recently, focus has been shifted to the synthesis of cadmium free quantum
dots. InP quantum dots are more appropriate because they are less cytotoxic and have a wide
emission range from the UV to near infra red region of the electromagnetic spectrum, which
makes them ideal candidates for in vivo applications as opposed to CdSe quantum dots.
However, the quantum yield of III-V quantum dots is less than 1% due to surface traps, dangling
bonds in the crystal lattice and high activation barrier for de-trapping as compared to II-VI
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semiconductors.7 Recently Peng et al reported InP/ZnS core–shell quantum dot synthesis using a
fatty amine; for this method the quantum yields reached up to 40%.8 A one step and one pot
method for the synthesis of highly luminescent InP with QYs of up to 30% and InP/ZnS QDs
with QYs of up to 60% was reported by Nann et al.9 More recently, Reiss et al synthesized
InP/ZnS QDs in a single step with quantum yield up to 70%.10 In the current work, InP/ZnS
quantum dots were incorporated for the first time into liposomes, making the InP/ZnS quantum
dots water soluble and biocompatible. The structural characterization of InP/ZnS quantum dots
demonstrated well preserved integrity of liposomes even after incorporation of InP/ZnS quantum
dots. The photostability studies of InP/ZnS QD-liposomes compared with the MHDA capped
quantum dots and InP/ZnS quantum dots showed that encapsulation with liposomes enhanced the
photostability of the InP/ZnS quantum dots. The effect of pH on the optical properties of
InP/ZnS quantum dots showed only less than 10% variation in the PL intensity of InP as opposed
to 35% variation in PL intensity of InP/ZnS coated with mercaptosuccinic acid reported
previously by Yong et al.11 The results demonstrated advantages of InP/ZnS QD-liposomes over
InP/ZnS quantum dots. The InP/ZnS QD-liposome complexes thus synthesized will find a wide
range of biological applications such as bioimaging, bioassays, and immunoassays.
Among several unique characteristics one of the most popular features of quantum dots is
their ability to multiplex. This unique property makes it possible to simultaneously detect
different emission peaks when different sizes of QDs are excited with a single wavelength.
Quantum dots have been used in multiplexed assays by several studies by different research
groups to detect biomolecules such as multiple DNA targets to specific neurotoxins. In the
current study a new method of CdSe/ZnS quantum dot based fluorescence immunoassay has
been developed for simultaneous detection of the cardiac biomarkers troponin T and troponin I.
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Currently, several immunoassay methods are available commercially for the detection of
troponin I and troponin T separately, most of them are based on UV absorbance, and some of
them are based on fluorescence.12-14 However, the detection limits of current troponin assays do
not allow detection of normal cardiac troponin levels in healthy controls.15 Thus lower detection
limits with improved assay sensitivity and precision are required to improve assessment of risk.
A sandwich immunoassay was performed with capture antibodies immobilized on a 96-well
plate. After binding targeted biomarkers to capture antibodies, detection antibodies conjugated to
CdSe/ZnS quantum dots were then bound to the specific biomarkers forming a sandwich
complex. The experimental conditions optimized to perform individual assays for the detection
of troponin T and troponin I have achieved a detection limit of 0.1 pg/mL compare to current
detection limits of 10 pg/mL for troponin T and 22 pg/mL of troponin I. The detection limits
allows the diagnosis of troponin levels in healthy controls. The method was highly specific for
the biomarkers troponin T and I with no observed cross reactivity with different antigens
troponin T, troponin I, 1% bovine serum albumin (BSA), and creatine kinase (CK-MB). The
multiplex assay was able to detect two biomarkers simultaneously that will yield a high
throughput diagnostic tool for heart attack. The experimental results support the success of the
method in controlled aqueous (buffer) solution. Therefore to further establish the applicability of
the method in real samples the method has to be verified in PBS buffer with high salt
concentrations and eventually in serum samples. In addition the method also needs improvement
in terms of fast response time for onsite analysis of the biomarkers that will expedite patient’s
diagnosis and treatment procedures.
According to recent United States statistics, the first symptom of atherosclerosis is heart
attack or sudden cardiac death among the majority of men and women with this disease. This
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situation is indicative of the lack of diagnostic methods in early stages of atherosclerosis. Recent
research has shown the presence of biomarkers at different stages of atherosclerosis, such as
molecular proinflammatory biomarkers, plaque destabilization and plaque rupture biomarkers.
These markers can help predict future cardiovascular disease not only in healthy individuals, but
also in patients with acute coronary syndrome. The method described above for the detection of
heart attack markers was extended to detect atherosclerosis biomarkers. Thus this study aims at
development of QD based fluorescence immunoassay for simultaneous detection of three
atherosclerosis markers MCP-1, IL-15, and IL-18 that play significant roles in two important
stages of atherosclerosis, fatty streaks and plaque destabilization. Current work only shows the
optimized experimental conditions to perform individual assays for the detection of MCP-1 and
IL-15. The method was able to detect as low as 100 pg/mL of MCP-1 and 10 pg/mL of IL-15.
The inability to achieve better detection limits was attributed to low affinity between the antigenantibody pairs used in this method. Therefore a new approach was proposed to improve the
detection limits by incorporating QDs into silica beads before binding to the detection antibodies.
Incorporation of large number of QDs into a single silica bead will not only improve signal
intensity but also will help improve results with low affinity antigen-antibody pairs. Furthermore,
to complete the study optimization of IL-18 and multiplexing of the assay have to be done for
simultaneous detection of the biomarkers. Also the applicability of the method in real samples
collected from patients has to be established. Despite the limitations the preliminary results
support the development of multiplex assay to detect three biomarkers simultaneously that will
yield reliable, sensitive, efficient methods for diagnosis of atherosclerosis.
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6.1 Limitations and Future Studies
Quantum dots have several advantages over organic dyes as fluorescence probes however
they pose cytotoxicity that limits their applications especially for in vivo studies. Hence there is
greater inclination of research towards the synthesis of cadmium free QDs in which InP/ZnS
QDs emerged as highly potential candidates. InP/ZnS QDs were first time incorporated into
liposomes in this dissertation which not only makes them biocompatible but also have shown to
exhibit several advantages in comparison to InP/ZnS QDs. In future studies InP/ZnS QDliposomes cytotoxicity needs to be verified. Also cellular internalization studies of the QDliposomes would be helpful in demonstrating their potential use in cellular applications. Finally
with their emissions in wide range of wavelengths from blue to near infra red region their
applicability can be extended to various areas including cellular labeling, microbiology labeling,
bioassays, and in NIR imaging.
Quantum dot based immunoassays are promising tools in simultaneous detection of
several biomarkers that will need improvement for their implementation in clinical diagnostics.
The first one being no reliable method for the estimation of number of antibodies attached to one
quantum dot which might lead to failure in discrimination of different samples especially at
lower concentration ranges. Second one is cytotoxicity; though not a major obstacle in using the
QDs for in vitro applications may have negative consequences on the lab personnel working with
QDs in comparison to commercially available immunoassay kits. Replacing the CdSe QDs with
InP QDs would greatly minimize these negative consequences. Finally the time and labor might
also be a limiting factor in the QD based fluoroimmunoassays as it involves several
bioconjugation steps. Taking these into account and the methods developed in this dissertation
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with further improvisation, the applicability has to be verified in future with serum samples
collected from the patients for clinical applications.
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